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Summary 
 
LINE-1 retrotransposition is tightly restricted but, unlike epigenetic silencing, the 
post-transcriptional repression mechanism is obscure. Here, we show that LINE-1 
mRNA 3’ ends are pervasively uridylated in various human cellular models and in 
mouse testes. This is accomplished by TUT4 and TUT7 enzymes in functional co-
operation with the helicase/RNPase MOV10, which counteracts RNA chaperone 
activity of the L1-ORF1p retrotranspozon protein. Uridylation potently restricts LINE-1 
retrotransposition by a multilayer mechanism depending on differential subcellular 
localization of the terminal uridyltransferases. We propose that uridylation blocks 
initiation of reverse transcription by a lack of base-pairing of uridylated LINE-1 mRNA 
3’ end with a genomic stretch of Ts exposed by the endonucleolytic activity of L1-
ORF2p. Moreover, LINE-1 mRNAs are destabilized by TUT4-mediated uridylation in 
cytoplasmic foci. Our results provide the first mechanistic model for the post-
transcriptional restriction of LINE-1, revealing the main physiological role for TUT4/7-
mediated uridylation in maintaining genome stability. 
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Introduction 
 
Long INterspersed Element-1 (LINE-1, thereafter L1) is a group of active non-long 
terminal repeat retrotransposons. Through their ability to mobilize and insert into new 
genomic locations via a copy-and-paste mechanism, L1s have acted as a major 
dynamic force that shaped the genomes of humans, mice and other vertebrate 
species (Cordaux and Batzer, 2009, Faulkner and Garcia-Perez, 2016). Roughly 
500,000 L1 copies constitute ~17% of the human genome. Due to 5' truncations, 
rearrangements and mutations, most L1s can no longer mobilize. However, in an 
average human genome 80-100 L1 copies remain potentially active with just <10 
highly active L1 copies accounting for genetic variation and mosaicism in humans 
(reviewed in Beck et al., 2011, Hancks and Kazazian, 2012).  
Active L1 elements are ~6-7 kb in length and contain: a 5' untranslated region (UTR), 
two ORFs separated by a short linker sequence, and a short 3' UTR. The 5' UTR 
contains an internal RNA polymerase II promoter (Swergold, 1990) that drives 
transcription of the bicistronic L1 mRNA which is translated by an unconventional 
mechanism into L1-ORF1p and L1-ORF2p (Alisch et al., 2006, Dmitriev et al., 2007). 
L1-ORF1p is a 40 kDa nucleic acid chaperone which, upon translation, forms 
homotrimers and tightly encapsulates its parental mRNA (Callahan et al., 2012, 
Khazina et al., 2011, Martin et al., 2003, Naufer et al., 2016). The 150 kDa L1-ORF2p 
functions as an endonuclease (Feng et al., 1996) and reverse transcriptase (Mathias 
et al., 1991). L1-ORF2p is translated far less efficiently than L1-ORF1p (Alisch et al., 
2006) and is thought to associate with the poly(A) tail of L1 mRNA (Doucet et al., 
2015). L1-ORF2p, together with L1-mRNA encapsulated by L1-ORF1p, form a 
minimal retrotransposition particle, or L1-RNP (Doucet et al., 2010, Kulpa and Moran, 
2005). Once in the nucleus, L1-RNPs generate a new L1 insertion in the genome 
through a mechanism termed target-primed reverse transcription (TPRT; Jurka, 
1997). 
Many cellular pathways act to restrict retrotransposition at transcriptional and post-
transcriptional levels (reviewed in Goodier, 2016, Pizarro and Cristofari, 2016, Yang 
and Wang, 2016). However, the mechanism of the latter is not clear. Even for the 
well-established retrotransposition and retrovirus restriction factor, the RNA helicase 
MOV10 (Arjan-Odedra et al., 2012, Choi et al., 2018, Goodier et al., 2012, Li et al., 
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2013, Lu et al., 2012, Skariah et al., 2017), the exact mechanisms of action remain to 
be clarified.  
Here, we examined 3' uridylation of L1 retrotransposons. The uridylation process 
involves addition of non-templated uridine residues to 3' ends of RNA by terminal 
uridyltransferases (TUTases). In fact, cytoplasmic uridylation mediated by two multi-
domain TUTases, TUT4 and TUT7, is an abundant and important modification of 3' 
ends of a variety of cellular RNAs (reviewed in Labno et al., 2016a, Norbury, 2013) 
including histone mRNAs (Mullen and Marzluff, 2008, Schmidt et al., 2011), let-7 pre-
miRNAs (Heo et al., 2012, Faehnle et al., 2017), mature miRNAs (Thornton et al., 
2014), canonical mRNAs (Lim et al., 2014) and multiple non-coding RNAs (Labno et 
al., 2016b, Pirouz et al., 2016, Ustianenko et al., 2016). Although monouridylation of 
pre-let7 is involved in biogenesis of mature miRNAs (Heo et al., 2012), in all other 
known instances uridylation is linked to RNA destabilization, with an apparent role in 
apoptosis-inducing global mRNA decay (Thomas et al., 2015). Another 
uridyltransferase in human cells is nuclear TUT1 which is involved in the maturation 
of U6 snRNA (Mroczek and Dziembowski, 2013). 
Herein, we present a mechanism for L1 retrotransposition restriction. First, we 
demonstrate abundant uridylation of endogenous L1 mRNAs in a variety of human 
cell types and mice testes and show that uridylated L1 mRNAs have severely 
compromised retrotransposition, despite their apparent persistence in the cell and 
lack of major effects of uridylation on L1-ORF1p and L1-ORF2p abundance. 
Uridylation involves cooperation between MOV10 helicase and TUT4 and TUT7, as 
revealed by a combination of in vivo and in vitro experiments. We speculate that 
uridylation-dependent restriction occurs by the inhibition of initiation of reverse 
transcription by L1-ORF2p during TPRT and partially by enhanced L1 mRNA decay.  
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Results 
 
TUT4/7 restrict retrotransposition of active human L1s 
 
New genomic insertions of L1 retrotransposons by TPRT rely on the endonuclease 
and reverse transcriptase activities of L1-ORF2p, which first nicks genomic DNA 
preferentially within a 5´-TTTT/AA consensus sequence, exposing an oligo dT stretch 
that, after base pairing with the L1 RNA poly(A) tail, serves as a primer for reverse 
transcription (Doucet et al., 2015, Jurka, 1997, Monot et al., 2013). 
We hypothesized that uridylation of L1 mRNA might interfere with the base-pairing 
during TPRT, leading to reduction of L1 retrotransposition. We therefore tested the 
effect of all human TUTases – cytoplasmic TUT4 and TUT7 and nuclear TUT1 on 
human L1 retrotransposition, using a reporter assay in cultured cells (Moran et al., 
1996, Ostertag et al., 2000; reviewed in Kopera, et al, 2016). In the assay, cells are 
transfected with a plasmid encoding a retrotransposition-competent L1 element 
tagged with a retrotransposition indicator cassette (enhanced green fluorescent 
protein – EGFP or neomycin antibiotic resistance) cloned in the antisense orientation 
in the 3' UTR of the L1 (Figure 1A).  
We co-transfected HEK293T cells with an active human L1 reporter tagged with the 
megfpI cassette (Ostertag et al., 2000) together with plasmids for overexpression of 
either wild-type TUT4, TUT7, TUT1 or TUT4 and TUT7 catalytically inactive mutants. 
As controls, we used plasmids that overexpress MBP protein, a plasmid for 
overexpression of MOV10 (positive control for retrotransposition restriction) and a 
mutant retrotransposition-incompetent L1 (JM111; Moran et al., 1996). L1 
retrotransposition was assessed by flow cytometry. Notably, overexpression of wild-
type TUT4 and TUT7, but neither of their catalytic mutants or wild-type TUT1, 
inhibited retrotransposition >5-fold (Figure 1B). As expected, L1 retrotransposition 
was reduced by MOV10 overexpression and the mutant L1 construct failed to 
retrotranspose (Figure 1B). Additional controls revealed that all co-transfected factors 
were expressed at similar levels and did not elicit cytotoxicity (Figure S1A, left panel, 
Figure S1B). Furthermore, we tested other known human TENTs (TErminal 
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NucleotidylTransferases) including TENT2, TENT4B and a member of a novel TENT 
family – TENT5C, a terminal polyadenylase (Mroczek et al., 2017). Neither of these 
enzymes significantly reduced L1 retrotransposition (Figure S1A,C). 
To validate these results, in a reciprocal experiment we co-transfected L1 reporter 
with siRNAs targeting TUT4 and TUT7 or MOV10. Accordingly, silencing of TUTases 
increased retrotransposition by ~2.2-fold relative to the controls (non-targeting 
siRNAs, Figure 1C, Figure S1D,E). However, when only TUT4 or TUT7 was depleted, 
we observed a stronger effect for TUT7 (~2-fold) than for TUT4 (~1.5-fold). Silencing 
of TUT1 had no effect (Figure 1C, S1F). 
Finally, we used a different cell line (HeLa-HA) and a mneoI retrotransposition 
indicator cassette, which, upon retrotransposition, confers resistance to G418 (Moran 
et al., 1996). Retrotransposition frequency was then estimated by the number of 
G418-resistant colonies (Figure 1A). Depletion of eitherTUT7, TUT4 or MOV10 
resulted in a significant increase in the number of G418-resistant foci (Figures 1D, 
S1G). 
Taken together, we show that TUT4 and TUT7 strongly reduce L1 retrotransposition 
to levels similar to those observed with MOV10. On the contrary, TUT1 and other 
human TENTs do not affect L1 retrotransposition. 
 
L1 mRNAs are uridylated 
 
To uncover the molecular foundation of the observed L1 retrotransposition restriction 
by TUT4 and TUT7, we investigated 3’ ends of endogenous and reporter L1 mRNAs, 
using 3' RACE-seq with individual transcript barcoding and TAIL-seq bioinformatics 
pipeline (Chang et al., 2014, Figure S7, Table S1).  
We first investigated endogenous L1 mRNAs in a panel of human cells and in testes 
of P10 mice in which L1s are naturally overexpressed. Remarkably, ~30–50% of all 
L1 mRNAs were uridylated (Figure 2A,B). Furthermore, a significant fraction of L1 
mRNAs did not possess poly(A) tails, and were instead truncated within their 3’ UTRs, 
while 10-25% of those non-poly(A) were oligouridylated (Figure 2B, U-tail). Our data 
revealed that endogenous L1 mRNAs contained mostly only short (uridylated) 
oligoadenine tails of ~15 As and ~3 Us (Figure S2A, Table S2). Using human 
Warkocki et al. 
7 
embryonic carcinoma cells (PA-1) we showed that the combined depletion of TUT4 
and TUT7 significantly lowered the fraction of uridylated L1 mRNAs, with a 
concomitant increase in the adenylated fraction (Figure 2C and Figure S2B). This 
was also visible for some control mRNAs including ACTB, GAPDH and PABPC4 
(Figure S2A,C). 
Next, we investigated the uridylation status of reporter L1 mRNAs in HEK293 cells. 
Notably, only ~50% of the L1 reporter transcripts had adenylated 3' ends. Moreover, 
we observed a statistically significant increase in uridylation of L1 reporter mRNAs in 
TUT7 WT, TUT4 WT and MOV10 overexpressing cells in comparison to the 
controls: MBP and the catalytic mutants of TUT7 and TUT4 (Figure 2D). The 
increase in uridylation was accompanied by a decrease in adenylation of L1 reporter 
mRNAs (Figure 2E). Most of the uridylated L1 reporter 3’ ends contained on average 
~2.5 Us in controls and ~3.5 Us in TUT4, TUT7 and MOV10 overexpression, 
although >10 Us oligouridine tails were also present (Figure S2D,E). When TUT1 and 
TENT5C were overexpressed, we observed a non-significant increase in L1 reporter 
uridylation (Figure 2F). To further test whether uridylation under either TUT4, TUT7 
or MOV10 overexpression is specific to L1 mRNA or general, we performed 3’ 
RACE-seq of mRNAs: ACTB, GAPDH, PABPC4 and SOGA2 (the latter two reported 
as highly uridylated mRNAs in HeLa cells; Chang et al., 2014). We did not observe 
effects on uridylation of these mRNAs (Figure S2F), thus demonstrating that under 
our experimental conditions L1 reporter mRNAs were preferentially uridylated. We 
then tested effects of TUT4, TUT7 and TUT1 depletion on L1 reporter mRNA 3’ ends. 
As expected, depletion of both TUT4 and TUT7 resulted in a significant drop of L1 
uridylation and a concomitant increase in their adenylation (Figure 2G,H, Figure S2H). 
The same effects were observed for the 4 control mRNAs (Figure S2G). Finally, 
consistent with the data on endogenous L1 mRNAs, the depletion of TUT1 had no 
effect (Figure S2I).  
To retrotranspose, L1 RNPs must access the nucleus. Thus, we performed 3’ RACE-
seq on RNAs isolated from the nucleus and cytoplasm of PA-1 cells. In stark contrast 
to control mRNAs (ACTB, GAPDH and SOGA2), that were present mainly in the 
cytoplasm, endogenous L1 mRNAs were evenly distributed among cytoplasmic and 
nuclear compartments (Figure 2I). Moreover, a significant fraction of uridylated L1 
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mRNAs was detected in the nuclei, suggesting that nuclear re-import of L1 RNPs is 
not affected.  
In sum, we demonstrate abundant uridylation of L1 mRNAs. Moreover, the data raise 
a possibility that MOV10 may functionally co-operate with TUT4 and TUT7 in 
uridylating L1 mRNAs. 
 
Inclusion of 3' uridines restricts L1 retrotransposition  
 
To test whether 3' uridylation of L1 mRNAs affects retrotransposition, we generated a 
set of L1 megfpI-tagged reporters containing a tRNA-like element that is cleaved off 
at its 5' end by endogenous nuclear RNase P, thus yielding L1 reporters with 
precisely defined 3' ends. We prepared L1 reporters ending in homonucleotide tracts 
of 19A, 26A, 40A, 7U and 26U, and reporters containing 19A, 26A or 40A plus a 
variable number of 3’ uridines including: 19A1U, 19A3U, 26A1U, 26A2U, 26A3U, 
26A4U, 26A5U, 26A6U, 26A14U, 26A26U, 40A1U and 40A2U, as well as a reporter 
lacking any homonucleotide tract – NT (Figure 3A). Using 3’ RACE-seq we confirmed 
that the reporters acquire the pre-designed 3’ ends in vivo (Figure S3A,B). 
Remarkably, inclusion of even a single uridine after a poly(A) tail significantly reduced 
retrotransposition by up to ~35% (Figure 3B). The reduction level increased gradually 
with each uridine included at the 3’ end of the reporters. The presence of 5-6 uridines 
reduced retrotransposition to ~25% observed with the non-uridylated 26A reporter. 
Oligouridylated reporters lacking any poly(A) – 7U and 26U, essentially did not 
support retrotransposition. 
A possible explanation for these results could be a reduction in the amounts of 
uridylated reporter L1 mRNAs. We addressed this question by measuring steady-
state levels of a few selected reporters by RT-qPCR. The oligouridylated L1 reporters 
were observed at lower steady-state levels than their non-uridylated counterparts 
(Figure 3B). Nevertheless, the effects were insufficient to explain the observed 
reduction in retrotransposition. Importantly, we detected substantial amounts of the 
26A26U, 7U and 26U L1 reporter mRNAs (at ~1/3 of the 26A reporter levels) despite 
their inability to support retrotransposition. This suggests that the effect of uridines on 
RNA levels was an important but not the only factor in restricting retrotransposition. 
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We then tested whether L1-ORF2p can reverse-transcribe substrates ending with 
uridine residues. We used a modified version of the L1 Element Amplification 
Protocol (LEAP, Kulpa and Moran, 2006) with the 26A and 26U L1 reporters and 3' 
adapters comprising 12Ts or 12As and a universal primer sequence to specifically 
prime reverse transcription of either adenylated or uridylated RNAs by L1-ORF2p. 
Finally, the cDNAs were amplified by PCR with reporter and 3' adapter-specific 
primers (Figure 3C). The expected amplification product of ~100 bp was only 
observed with complementary adapter-reporter pairs (Figure 3D, compare lanes 2, 5 
with lanes 3, 4). To further ascertain genuine reverse transcription of the 26U 
reporters, we cloned and sequenced the 12A-primed LEAP products (lane 5 in Figure 
3D). Notably, 20/24 clones had U-tails of a median length of 21.5U, including clones 
containing 26Us (Figure S3C,D). 
We conclude that 3’ uridines abolish L1 retrotransposition, partially through lowering 
L1 mRNA availability, and that L1-ORF2p can specifically reverse transcribe 
uridylated L1 mRNAs. 
 
Differential effects of TUT4 and TUT7 on L1 mRNA abundance, stability and its 
translation 
 
The impact of TUT4, TUT7 and MOV10 on L1s’ oligouridylation and 
retrotransposition potential prompted us to test their effects on L1 mRNA steady-state 
levels, stability and on translation of L1 proteins. 
Northern blotting of poly(A)-selected RNAs is the gold standard for detecting and 
quantifying full-length L1 mRNAs (Figure S4A). To account for our discovery of a 
substantial fraction of oligouridylated and 3’ truncated L1 mRNAs, we omitted the 
poly(A) selection in our northern blot analyses and could readily detect abundant 
expression of full-length L1 reporter mRNAs (Figure 4A). Notably, we observed a ~50% 
reduction in the amounts of L1 reporter mRNAs relative to control (MBP) in TUT4 WT 
and MOV10 overexpressing cells, which is in line with the drop in retrotransposition 
observed under these conditions (Figure 4A, B). Surprisingly, we observed increased 
amounts of L1 mRNAs in TUT7 WT overexpressing cells (Figure 4A, B), consistent 
with our idea that L1 mRNA availability is one, but not the key, determinant for L1 
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retrotransposition. Although the reason for increased levels of L1 mRNA in TUT7 
overexpressing cells remains unclear, the differential effects of TUT4 and TUT7 on 
steady-state levels of L1 reporter mRNAs could possibly be explained by differential 
localisation of those enzymes in the cell. In fact, we observed that in HEK293 cells 
TUT7 was a pan-cytoplasmic protein, but TUT4 and MOV10 were cytoplasmic and 
clearly co-enriched in cytoplasmic foci (Figure 4C,D). To note, L1-ORF1p co-
localized with both TUT4 and MOV10 in the cytoplasmic foci (Figure S4B, Table S3), 
some of which could be P-bodies or Stress Granules (SG) as previously described 
(Doucet et al., 2010). 
We next determined the stability of L1 reporter mRNAs using actinomycin D 
treatment and multiplex Taq-Man RT-qPCR. In general, reporter L1 mRNAs are very 
stable species, exhibiting an overall stability comparable to GAPDH mRNA, and 
unlike c-Myc mRNA which decayed rapidly (Figure 4E). Consistent with the northern 
blot data, we observed destabilization of L1 mRNAs when compared to GAPDH, in 
TUT4 WT overexpressing cells, while TUT7 WT overexpression did not significantly 
destabilize L1 mRNAs. Surprisingly, in MOV10 overexpressing cells L1 mRNAs were 
as stable as GAPDH, suggesting that a fraction of L1 mRNAs is generally stable and 
insensitive to MOV10-induced RNA degradation (Figure 4E). 
To complement these studies, we tested whether endogenous L1 RNAs are 
influenced by TUT4, TUT7 and MOV10. We analyzed L1s from HEK293 cells 
overexpressing either wild-type TUT4, TUT7 or MOV10 or depleted of these proteins 
and from PA-1 cells depleted for both TUT4 and TUT7 and TUTases plus MOV10 
using RNA-seq (Figure S4C, D, E). In line with the northern blot results, 
overexpression of TUT7, but not of MOV10 or TUT4, significantly increased 
expression of most of L1 subfamilies (Figure 4F, Table S4). Consistently, we did not 
observe statistically significant differences in L1 mRNA abundance in HEK293 and 
PA-1 cells following depletion of TUT4 and TUT7, MOV10 or both TUTases and 
MOV10 (Figure 4G, Figure S4F, Table S5). In addition, we also conducted RT-qPCR 
to analyze changes in L1Hs-Ta mRNAs, but we did not observe statistically 
significant changes (Figure S4G,H,I). When combined, these results suggest that 
regulation of L1 retrotransposition is mostly achieved by qualitative, rather than 
quantitative, changes on its mRNAs. 
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Finally, we tested whether TUT4, TUT7 and MOV10 influence translation of the L1-
encoded proteins. To do that, we constructed several plasmids encoding active L1s 
in which either L1-ORF1p or L1-ORF2p, or both, were fused to a fluorescent protein, 
or which encoded L1-ORF1p tagged with FLAG (Figure S4J,K,N,O). We only 
detected a slight, but statistically significant reduction in L1-ORF1p expression (and 
less so in L1-ORF2p) in cells overexpressing MOV10, and to a lesser extent wild-
type TUT7 and TUT4 (Figures 4H,I and S4L,M,P,R). 
Summarising, L1 mRNAs are stable mRNAs. Their steady-state levels, stabilities and 
translation are only moderately influenced by TUT4, TUT7 and MOV10. We 
speculate that the different effects of TUT4 and TUT7 on L1 mRNA levels and 
stability may be explained by differential subcellular localization of the TUTases, 
since only TUT4 is enriched in cytoplasmic foci. 
 
TUTases associate with MOV10 
 
The apparent effect of MOV10 on L1 uridylation (Figure 2D) prompted us to 
investigate whether MOV10 might be functioning in the same pathway with (as?) 
TUTases. To this end, we first tested interaction partners of TUT4 and TUT7 by 
establishing HEK293 FLP-IN T-Rex cell lines stably expressing either TUT4 or TUT7 
with an EGFP tag at their N termini (Figure S5A-G). 
To stabilize evasive interactions, we performed in vivo cross-linking of proteins with a 
bifunctional primary amine-reacting cross-linker: dithiobis(succinimidyl propionate) 
(DSP). Co-immunoprecipitation experiments (co-IP) were carried out for cell lines 
expressing either EGFP-TUT4, EGFP-TUT7 or EGFP (control) revealing MOV10 as 
the most specifically enriched protein with both TUT4 and TUT7 (Figure 5A,B, Table 
S6). In agreement with the differential subcellular distribution of TUTases, TUT4 
associated stronger with MOV10 than TUT7 (Figures 4C, S5D,E). In a reciprocal co-
IP with EGFP-MOV10 we detected TUT4 by LC-MS/MS and TUT7 by a western blot 
(Figure 5C, Figure S5H, Table S7). Other specifically enriched proteins in MOV10 co-
IP experiments were IGF2BP2 (7 out of 7 co-IPs), UPF1 and FAM120A, to cite few 
examples. Thus, it is clear that MOV10 possesses a wider protein interactome than 
any of the TUTases. We next validated the interactions without DSP crosslinking and 
tested their RNA-dependence and stability (Figure 5D). In the EGFP-MOV10 co-IPs 
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TUT4 was enriched ~10-fold more than TUT7 (Figure 5D, right panel, lanes 9-13). 
Addition of RNase A significantly reduced the amounts of enriched TUTases in the 
co-IPs. A similar effect was observed when increasing concentrations of salt were 
used to wash the IP (Figure 5D, lanes 11-13). A poly(A)-interacting PABPC1 also co-
purified with EGFP-MOV10 and showed similar RNA-dependence and RNase A 
sensitivity as TUTases (Figure 5D). 
To test whether TUT7 interaction with L1 mRNA depends on MOV10, we performed 
an RNA-co-IP experiment employing UV RNA-protein cross-linking in vivo (Figure 
S5I-K). We observed superior enrichment (~600-fold) of L1 mRNAs in FLAG-TUT7 
co-IPs as compared to GAPDH (~60-fold) and normalized to control co-IPs with 
MBP-TUT7 lacking FLAG (Figure 5E). Importantly, depletion of MOV10 reduced the 
amount of enriched L1 mRNA in FLAG-TUT7 co-IPs by ~30% (Figure 5F). 
Overall, we show that TUT4, and to a lesser extent TUT7, associate with MOV10 in 
an RNA-dependent and salt-sensitive manner. Furthermore, we show that TUT7 
specifically interacts with L1 mRNA and that this interaction is partially MOV10-
dependent. 
 
MOV10 facilitates L1 uridylation by displacing L1-ORF1p 
 
To clarify the potential direct role of MOV10 in uridylating L1 mRNAs, we performed 
biochemical in vitro reconstitution experiments. L1-ORF1p has nucleic acid 
chaperone activity towards its encoding mRNA (Callahan et al., 2012). We therefore 
hypothesized that L1-ORF1p could prevent uridylation of the 3' end of L1 mRNA and 
that MOV10, known as a functional helicase (Gregresen et al., 2014) could 
counteract this effect. To test this hypothesis, we combined synthetic 32P-labelled 
RNA without or with MOV10 and without or with recombinant L1-ORF1p in increasing 
concentrations in a buffer containing ATP and UTP. Uridylation was initiated by the 
addition of TUT4 WT. L1-ORF1p indeed inhibited uridylation of RNA in a dose-
dependent manner (Figures 6A lanes 1-4, B, C and Figure S6A,B). In the presence of 
MOV10 and without L1-ORF1p, uridylation was also inhibited and the median lengths 
of oligouridine tails were shorter as in the control without MOV10 (Figure 6A lanes 5-
8, Figure 6B,C). Notably, with increasing rL1-ORF1p concentrations, MOV10 
counteracted the rL1-ORF1p adverse effect on RNA uridylation (Figure 6A,B,C). On 
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the other hand, the two other helicase/RNPase proteins tested: human SUV3 (Pietras 
et al., in revision) and yeast PRP2 (Warkocki et al., 2009) did not show such effects 
(Figure 6A,B). To further strengthen our observations, we performed RNase I 
footprinting experiments. We reasoned that L1-ORF1p would protect RNA from 
degradation by RNase I, unless its binding was hindered by MOV10 or it was actively 
removed by MOV10. L1-ORF1p indeed tightly protected the entire RNA molecule 
(Figure S6C, lanes 4, 5). Remarkably, when MOV10, in the presence of ATP, was 
allowed to bind RNA, it prevented protection of the RNA by rL1-ORF1p (Figure S6C, 
compare lanes 4-5 to lanes 7-8). Furthermore, if ATP was omitted or if a catalytically 
inactive MOV10 mutant was used (K530A, Gregresen et al., 2014), we did not 
observe RNA protection (Figure S6D,E), indicating that the helicase/ATPase activity 
of MOV10 is essential for removing rL1-ORF1p form L1 RNA. 
In sum, we demonstrated the ability of MOV10 to counteract the chaperone effects of 
L1-ORF1p on L1 mRNAs, and thus likely to set the stage for TUT4/TUT7-mediated 
uridylation. 
 
Discussion 
 
We discovered a novel mechanism of L1 restriction acting at the level of L1 mRNA, 
that relies on MOV10 helicase/RNPase activity followed by the uridylation of 3' ends 
of L1 mRNAs by TUTases. Poly(A) tracts were recently shown to be essential for L1 
retrotransposition (Doucet et al., 2015). Nevertheless, the actual global quality of L1 
mRNA 3' ends in human cells had not been investigated, in part due to technical 
challenges. We demonstrated pervasive 3' end uridylation of L1 mRNAs in human 
cells and mouse testes, comprising molecular niches where L1 are transcribed and 
thus post-transcriptional regulatory mechanisms are expected to operate. We 
propose that this abundant uridylation of L1 mRNAs provides a general, specific and 
efficient way of restricting retrotransposition of active L1s. 
This study allowed us to propose a model of MOV10-TUT4/TUT7-driven restriction of 
retrotransposition in mammalian cells (Figure 7). Following transcription in the 
nucleus, L1 mRNA is exported to the cytoplasm where translation of the L1-encoded 
proteins occurs. L1 mRNAs face MOV10, which had been shown in several 
independent studies to be a potent restriction factor of retrotransposition (Arjan-
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Odedra et al., 2012, Choi et al., 2018, Goodier et al., 2012, Li et al., 2013, Lu et al., 
2012, Skariah et al., 2017). Despite efficient production of L1-ORF1p, newly 
synthesized L1-ORF1p is likely in constant kinetic competition with MOV10 (Naufer et 
al., 2016). Direct binding of L1 mRNAs by MOV10 was previously demonstrated by 
cross-linking and immunoprecipitation (Gregersen et al., 2014), with the highest 
MOV10 occupancy just 5' and within the L1 3' UTR. Given its 5'→3' directionality 
(Gregersen et al., 2014), MOV10 likely moves along the L1 3' UTR toward the 3' end 
of this RNA to prime its uridylation by TUT4/TUT7 (Figures 6, S6). Although 
canonical uridylation of mRNA has been suggested to reduce their mRNA life time 
(Lim et al., 2014), in the case of L1 this effect seemed to depend on the subcellular 
localization of the uridylated L1 mRNA. Remarkably, canonically polyadenylated L1 
reporter and endogenous L1 mRNAs were slightly stabilized by TUT7 WT but not 
TUT4 WT (Figure 4), which might likely be explained by the differential localization of 
those enzymes in the cytoplasm with TUT4 enriched in cytoplasmic foci (Figure 4). 
Thus, here we showed for the first time that uridylation by TUT4 and TUT7 
differentially affects the fate of the uridylated RNA. Nevertheless, L1 reporters with 
pre-defined uridylated 3’ ends were indeed less stable than their adenylated 
counterparts (Figure 3). 
Uridylated endogenous L1 mRNAs could access the nucleus (Figure 2) where de 
novo L1 insertions are accumulated via TPRT (Jurka, 1997). During TPRT, the 
endonuclease activity of L1-ORF2p nicks dsDNA at a consensus sequence 
(5´TTTT/AA and variants), exposing a dT stretch that might promote base-pairing 
with the L1 poly(A) tail (Cost et al., 2002, Feng et al., 1996, Jurka 1997). The recently 
proposed “snap-Velcro” model for initiation of reverse transcription by human L1-
ORF2p (Monot et al., 2013) suggests that reverse transcription initiation is dependent 
on the degree of complementarity between the 3' end of the L1 mRNA and the 
exposed genomic DNA present at the site of L1-ORF2p endonuclease nicking. The 
most important residues for this process are the four 3'-most nucleotides (the “snap”). 
Thus, 3' uridylated L1 mRNAs could not base-pair efficiently with the short exposed 
dT genomic sequence, and as a consequence any uridine present at the 3' end of L1 
mRNAs will greatly diminish its competency for reverse transcription initiation (Figure 
3). While it is feasible that reverse transcription is initiated by L1-ORF2p within the 
poly(A) tract, irrespective of terminal 3’ uridines, the very weak retrotransposition 
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potential of the 26A6U, 26A14U and 26A26U L1 reporters (Figure 3) suggests that 
such internal priming must be highly inefficient. 
In sum, our data suggest that uridylation is a major mechanism of retrotransposition 
control in mammals, as it can act in all cell types where L1s retrotranspose. Although 
this hypothesis requires further testing, recent discoveries that female mice with a 
conditional double-knockout of TUT4/TUT7 are infertile (Morgan et al., 2017) is an 
interesting coincidence as high levels of L1 transcription occur in the germline. 
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Main Figure Legends 
 
Figure 1 TUT4 and TUT7 restrict L1 retrotransposition 
(A) Flowchart of the plasmid-based L1 retrotransposition assays that allow 
assessment of retrotransposition events by either flow cytometry-based monitoring of 
cellular EGFP fluorescence (megfpI reporter) or by counting drug-resistant colonies 
(mneoI reporter). 
(B) Effects of overexpression of either wild-type or mutant TUT4 or TUT7, wild-type 
TUT1, MOV10 or MBP (control) (each point=biological replicate) on L1 
retrotransposition in HEK293T cells. Negative control (neg. cntrl): a 
retrotransposition-defective reporter (L1-ORF1pR261A/R262A). The results of 
independent experiments were normalized relative to the control (MBP). Medians and 
interquartile ranges are shown. Statistical significance was calculated using one-way 
ANOVA and Tukey’s multiple comparison test (*** p<0.001, ** p<0.01, * p<0.05, in 
comparison to MBP). 
(C) Retrotransposition assay in HEK293T cells depleted of TUT7, TUT4 (alone or 
combined), MOV10 or TUT1 using siRNAs. A control with a non-targeting siRNA was 
included (CNTRL). Normalization was done relative to CNTRL. Statistical analysis 
was performed as in panel B (comparison to CNTRL shown). There is no significant 
difference between CNTRL and TUT1 and comparison to TUT1 instead of CNTRL 
gives the same statistical significances. 
(D) L1 retrotransposition assays in Hela-HA cells using mneoI L1 retrotransposition 
reporter assay. The results were normalized, relative to the control non-targeting 
siRNA (CNTRL). Medians and interquartile ranges are shown. Statistical analysis as 
in panel B. Shown are comparisons to CNTRL. Normalization was done to CNTRL. 
 
Figure 2 3’ RACE-Seq of L1 and control mRNAs 
(A) Fraction of uridylated endogenous L1 mRNAs in human embryonic carcinoma 
cells (PA-1), human embryonic stem cells (H9-hESCs), human neuronal progenitor 
cells (derived from hESCs, NPC) and in mouse testes (of P10 young mice; 4 mice, 8 
testes). 
(B) Distribution of 3’ tails in endogenous L1 mRNAs. The tails were assigned to one 
of four classes: U-tail (mono- and oligouridylated but not adenylated); AU-tail 
(adenylated and mono- and oligouridylated); “no tail” (neither adenylated nor 
uridylated, mostly truncated within the 3’ UTR); A-tail (oligo- and polyadenylated). 
(C) Effect of siRNA-mediated depletion of MOV10 or TUT4 and TUT7 on uridylation 
of endogenous L1 mRNAs in PA-1. Statistical significance was calculated using one-
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way ANOVA and Tukey’s multiple comparison test. The comparison and significance 
are shown relative to a non-targeting siRNA control (CNTRL, ** p < 0.01). 
(D) Uridylation of reporter L1 mRNAs in HEK293 cells under overexpression of MBP 
(CNTRL), wild-type and mutant TUT7, TUT4 or MOV10 as indicated. Statistical 
significance was calculated as in panel C. 
(E) Distribution of 3’ tails in reporter L1 mRNAs, visualized as in panel B under MBP, 
TUT4, TUT7 or MOV10 overexpression conditions as indicated. White dashed line 
and black dashed line indicate control sample levels of uridylated (U+AU-tails) and 
adenylated L1 mRNAs respectively.  
(F) Effects of overexpression of TUT1 and TENT5C on uridylation of reporter L1 
mRNAs in HEK293 cells. Statistical significance was calculated as in panel C. 
(G) Effects of depleting TUT4, TUT7, or both TUTases using siRNAs in HEK293 cells 
on uridylation of reporter L1 mRNAs. Statistical significance was calculated as in 
panel C. 
(H) Distribution of 3’ tails in reporter L1 mRNAs, visualised as in panel B under TUT4, 
TUT4 and TUT7, or TUT7 depletion conditions in HEK293 cells as indicated. 
(I) Distribution of endogenous L1 and control mRNAs’ (ACTB, GAPDH and SOGA2) 
3’ ends in the cytoplasmic and nuclear compartments of PA-1 cells. The numbers of 
sequenced 3' RACE reads are indicated and plotted assuming cyto+nuc=100%. 
Qualities of the mRNAs’ 3’ ends are color-coded as in panel B. 
 
Figure 3 Uridylation of L1 mRNA abolishes retrotransposition 
(A) Scheme of the L1 retrotransposition megfpI reporters used in this study. 
Immediately downstream of a reporter’s 3’ UTR, there is a defined sequence 
encoding a non-uridylated or differentially uridylated poly(A) (19A, 19A1U, 19A3U, 
26A, 26A1U, 26A2U, 26A3U, 26A4U, 26A5U, 26A6U, 26A14U, 26A26U, 40A, 40A1U, 
40A2U), 7U, 26U or the sequence is missing (“no-tail”; NT), all followed by a 
sequence encoding a tRNA-like element.  
(B) Retrotransposition frequency (black) and steady-state reporter mRNA levels (blue) 
with the reporters described in (A). For retrotransposition assays medians with 
interquartile ranges are shown (4 to 12 biological replicates). Blue boxes plus 
whiskers (Tukey’s) represent mRNA abundance (8 biological replicates) for the 
indicated reporters. Normalizations were done using the 26A reporter. One-way 
ANOVA and Tukey’s multiple comparison test were used to calculate statistics. All 
uridylated reporters support significantly (p<0.001) lower levels of retrotransposition 
than their non-uridylated counterparts. Steady states: 19A vs 19A3U – ns, 26A vs 
26A2U – ns, 26A vs 26A4U/6U/26U, 7U, 26U – p<0.001. 
(C) Scheme of the LEAP procedure with description. 
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(D) LEAP assays using plasmids carrying LINE-1 reporters ending with a defined 
sequence (26As or 26Us). The reporter used is indicated at the top, while the RT 
primer used in each LEAP reaction is indicated below (RT primer). Lanes 1 and 8, a 
DNA ladder (100bp to 1000bp with 100bp increments). The 100 and 500 bp bands 
are labelled. Negative controls (neg.cntrl) without RNPs were also included. 
 
Figure 4 Differential effects of TUT4 and TUT7 on L1 mRNA abundance, stability 
and translatability. 
(A) Northern blot of full-length reporter L1 mRNAs, expressed from a plasmid 
encoding a full-length L1.3 lacking a reporter cassette (JM101/L1.3 nomarker) under 
overexpression of MBP or N’MBP-tagged TUT4, TUT7 and MOV10 as indicated. 
GAPDH served as a loading control. Marks on the right indicate positions of the RNA 
reference ladder (in thousands of nucleotides) and the position of 28S and 18S 
rRNAs is indicated. 
(B) Quantification of 4 northern blots as in A (4 biological replicates, 3 independent 
experiments) normalized relative to the GAPDH signals and the MBP sample. One-
way ANOVA and Tukey’s multiple comparison test were used to calculate statistical 
significance (* p<0.05, *** p<0.001). Medians and interquartile ranges are shown. 
(C) Confocal microscopy pictures (maximal projections in z) depicting HEK293 cells 
transfected with plasmids encoding EGFP-TUT4 (top left panel) and mCherry-
MOV10 (top right, merge on bottom left panel) or EGFP-TUT7 (bottom right) to 
assess the subcellular localization of proteins. DNA was stained with Hoechst (cyan). 
White bars are scales (10 or 20m as indicated). 
(D) Quantitation of MOV10 containing foci in HEK293 cells that also contain TUT4 or 
TUT7 (based on co-transfection experiments and confocal microscopy as in C). For 
each condition (TUT4 vs TUT7) 30 cells were analyzed. Statistical significance was 
calculated using Wilcoxon signed rank test (P<0.0001). 
(E) Decay of L1 reporter and endogenous c-Myc mRNAs normalised to GAPDH 
mRNA. Actinomycin D was added to cell aliquots for 1-6 hrs, to block transcription, 
followed by RNA retrieval and estimation of RNA levels by RT-qPCR using 
multiplexing and Taq-Man probes. Results of 3 (c-Myc) or 4 (L1) independent 
biological replicates (time-course assays) are shown (mean values).  
(F) and (G) RNA-seq-based estimation of endogenous L1s expressed in HEK293 
cells overexpressing either TUT4, TUT7 (stable cell lines) or MOV10 (transient 
transfection) (F), or siRNA-depleted of these proteins (G). Uniquely mapped reads for 
76 Homo sapiens-specific L1s (after Repbase) were calculated and normalized to 
respective controls as indicated. Statistical significances were calculated by DESeq2 
for each respective condition pair using summarized counts of each L1 subfamily, 
and are shown above each pair in F. No significant changes could be observed in G. 
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(H) Analytical flow cytometry of cell populations co-transfected with a pJM101/L1.3-
O1EGFP-O2mCherry plasmid and plasmids overexpressing the indicated proteins. 
The pJM101/L1.3-O1EGFP-O2mCherry contains a full-length L1.3 element where 
the fluorescent EGFP and mCherry cDNAs were cloned in frame in the C-terminus of 
L1-ORF1p and L1-ORF2p respectively. Normalized EGFP and mCherry intensities 
for data from 8 biological replicates (3 independent experiments) are shown. 
Statistical significance was calculated as in panel B. 
(I) Western blot analysis of FLAG-tagged L1-ORF1p, translated from a full-length L1 
without a reporter cassette (pZW-L1RP-O1F; Figure S4N). Co-transfected plasmids 
are indicated at the top of the panel. Membranes were probed with anti-FLAG, anti-
tubulin and anti-MBP antibodies to detect respectively: overexpressed ORF1p-
FLAG, GAPDH (loading control) and MBP tagged proteins. Note that MBP migrates 
faster than any tagged protein and it is beyond the blot and thus not detected. 
 
Figure 5 RNA-dependent association of TUT4 and TUT7 with MOV10 
(A) Mass spectrometry of co-IPs with EGFP-TUT4 (6) and controls (6). Normalized 
mean intensity (semi-quantitative measure of protein abundance) and specificity 
(quotient of mean intensity in EGFP-TUT4 co-IP and in control co-IP) are plotted. 
Only hits identified in at least 3 out of 6 EGFP-TUT4 co-IPs are shown. 
(B) Mass spectrometry of co-IPs with EGFP-TUT7 (7) depicted as in panel A. Only 
hits identified in at least 4 out of 7 EGFP-TUT7 co-IPs are shown. 
(C) Mass spectrometry of co-IPs with EGFP-MOV10 (7) depicted as in panel A. Only 
hits identified in at least 3 out of 7 EGFP-MOV10 co-IPs are shown. 
(D) Flowchart of experiments used to study RNA-dependence and stability of the 
TUT4 and TUT7 interactions with MOV10 (left panel) and results of the respective 
experiment (right panel). Co-IP was done with EGFP-MOV10 as bait. Lanes 1-4: 
input and co-IP with lysates from control EGFP-expressing cells; Lanes 5-13: co-IP 
with lysates from EGFP-MOV10 expressing cells; Lanes 5-8: input proteins; Lanes 9-
13: enriched proteins without (lanes 9, 11-13) or with RNase A (lane 10), washed 
with increasing salt concentrations as indicated (lanes 11-13). Supernatants after 
incubation with (lane 14) or without (lane 15) RNase A. Blots were probed for MOV10, 
TUT4, TUT7, PABPC1 and GAPDH as indicated. Probing for GAPDH and control co-
IP was done to show the absence of non-specific interactions. 
(E) TUT7 co-IP with RNA after in vivo UV-crosslinking using monoclonal anti-FLAG 
antibodies and lysates from cells expressing reporter L1 RNAs and either FLAG-
TUT7 or control MBP-TUT7. Enrichment fold was calculated by 2^Ct method, 
dividing enriched L1 or GAPDH mRNAs in FLAG-TUT7 co-IP by their amounts non-
specifically enriched in MBP-TUT7 co-IP.  
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(F) Result of RNA co-IP after in vivo UV-crosslinking with FLAG-TUT7 from control 
cells (transfected with control non-targeting siRNA, CNTRL) or cells depleted of 
MOV10 (by siRNA), both transfected with plasmids encoding L1 reporter and FLAG-
TUT7. L1 enrichment was calculated by 2^Ct method of L1 mRNAs enriched in 
each condition and normalised to GAPDH recovered in each condition. 
(E) and (F) Results of four independent biological experiments are shown. Statistical 
significance was calculated using two-tailed Mann-Whitney test. 
 
Figure 6 MOV10 facilitates uridylation by competing with L1-ORF1p 
(A) RNA uridylation assay on a 5’ 32P-labelled synthetic RNA by recombinant TUT4 
in the absence or presence of recombinant L1-ORF1p and the indicated 
helicase/RNPase (HsMOV10, ScPRP2 or HsSUV3). Lane IN – input RNA; lanes 1-4 
– uridylation in the absence (1) or presence of increasing concentrations of rL1-
ORF1p (2-4); lanes 5-8 – as in lanes 1-4 but in the presence of HsMOV10; lanes 9-
12 – as in lanes 1-4 but in the presence of ScPRP2; lanes 13-16 – as in lanes 1-4 but 
in the presence of HsSUV3. The ladder on the right of the panel indicates appended 
Us. 
(B) RNA uridylation levels in the absence or presence of the indicated helicase 
proteins were plotted as functions of rL1-ORF1p concentration. Medians of 4 
independent replicates as in panel A.  
(C) Results of 5 independent RNA uridylation experiments as in A in the absence or 
presence of MOV10. Statistical significances were calculated using two-way ANOVA 
and Bonferroni multiple comparison test. 
 
Figure 7 Model of restriction of L1 retrotransposition by uridylation 
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Supplementary Figures Legends 
 
Figure S1 Control experiments for plasmid-based L1 retrotransposition assays, 
Related to Figure 1 
(A) Western blotting to show expression of N’-MBP-tagged wild-type and mutant 
TUT4, TUT7, MOV10 (lanes 1-5), N’-FLAG-tagged mutant and wild-type TUT7 and 
MOV10 (lanes 6-8), C’-FLAG-tagged TENT4B, TENT2, TUT1 and TENT5C (lanes 9-
12). Blots were probed with mouse monoclonal antibodies against MBP or rabbit 
polyclonal antibodies against FLAG. A probing for -tubulin and ponceau S staining 
were added as loading controls. A black arrow points to weakly expressed TENT2-
FLAG in lane 10.  
(B) and (D), A plasmid encoding EGFP was used to test transfection efficiencies and 
toxicity (EGFP expression) concomitantly with co-transfection of a plasmid 
overexpressing wild-type or mutant TUT4, TUT7, MOV10 or MBP (CNTRL, panel B) 
or concomitantly with siRNA-directed depletion of both TUT4/7, TUT4, TUT7, MOV10 
or non-targeting control (CNTRL, panel D). Data for 9 biological replicates (3 
independent experiments; panel B) and 3-6 biological replicates (2 independent 
experiments; panel D) were normalized to controls. Means with SEM are plotted. No 
significant differences were observed as assessed by one-way ANOVA and Tukey’s 
multiple comparison test. 
(C) L1 retrotransposition assay in HEK293T cells with L1-megfpI reporters and 
concomitant overexpression of the indicated protein (as in panel A). Normalisation 
was done to TUT7 MT. Statistical significance was calculated using one-way ANOVA 
and Tukey’s multiple comparison test. Statistical significance of TUT7 WT condition 
versus TUT7 mutant and the TENTs is shown (*** p<0.001). 
(E) Western blotting to test depletion of endogenous TUT4, TUT7, both TUTases or 
MOV10 by siRNAs (probed with specific antibodies; probing with -tubulin was used 
as a loading control). Cells were co-transfected with the L1 megfpI reporter 
concomitantly with siRNAs. Cells were collected on day 4 post-transfection and split 
for flow-cytometry and western blotting. An asterisk marks an unspecific band 
detected by the anti-TUT7 antibodies (the band can be used to assess loading). 
Probing with the anti--tubulin mouse monoclonal antibodies showed 2 bands and 
was not used in other blots in the paper. 
(F) RT-qPCR estimation of TUT1 depletion at mRNA level by siRNAs at day 3 post-
transfection (in cells co-transfected with the L1 megfpI reporter). Expression was 
normalized to control.  
(G) Western blotting to test depletion of TUT4 and TUT7, MOV10 or both TUTases 
and MOV10 in HeLa-HA cells under conditions used for retrotransposition assay with 
the mneoI reporter. Cells were collected at day 3 post-transfection (after co-
transfection with L1-mneoI plasmids). 
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Figure S2 3’ RACE-seq of endogenous and reporter L1 mRNAs and of control 
cellular mRNAs, Related to Figure 2 
(A) Distribution of U-tails, AU-tails and A-tails in endogenous L1, ACTB, GAPDH, 
PABPC4 and SOGA2 mRNAs (as indicated) possessing non-templated 3' end 
nucleotides in the indicated cells/organs: PA-1 cells, human embryonic stem cells 
(H9), human neuronal progenitor cells (NPC) and in mouse testes (MT). The fraction 
of transcript 3’ ends is shown in the y axis with total set to 100%. Tails were binned in 
10-nucleotide bins (but 1-9 and 60+) according to their length and are visualised in x 
axis. A black dashed line overlaid onto the graphs and represents total tail-length 
distribution, normalised to 100% and shown as % of total transcripts (y axis).  
(B) Distribution of 3’ tails in endogenous L1 mRNAs in PA-1 cells transfected with 
control non-targeting siRNA (CNTRL) or siRNAs against MOV10 or TUT4 and TUT7. 
The tails were assigned to one of four classes: U-tail (mono- and oligouridylated but 
not adenylated); AU-tail (adenylated and mono- and oligouridylated); “no tail” (neither 
adenylated nor uridylated, mostly truncated within the 3’ UTR); A-tail (oligo- and 
polyadenylated). 
(C) Uridylation of control mRNAs: ACTB, GAPDH and PABPC4 (as indicated) in PA-
1 cells transfected with control non-targeting siRNA (CNTRL) or siRNAs against 
MOV10 or TUT4 and TUT7. Statistical significance was calculated using one-way 
ANOVA and Tukey’s multiple comparison test significance (*** p<0.001). No 
statistical significance was reported between CNTRL and MOV10 depletion. 
(D) Distribution of U-tail lengths in reporter L1 mRNAs in HEK293 cells under 
overexpression of the indicated proteins. The U-tails were grouped according to the 
number of uridines. Data were normalized to all mRNAs for a given condition. 
(E) Examples of 3’ RACE clones with reporter L1 mRNAs, to show the presence of 
oligouridylated (1,2) and oligoadenylated and oligouridylated 3’ ends (3). Dashed 
lined boxes indicate the presence of non-templated nucleotides. Blue background 
indicates 5’ end of the 3’ adapter used (different for 1, 2 and 3). 
(F) Uridylation of control mRNAs: ACTB, GAPDH, PABPC4 and SOGA2 (as 
indicated) in HEK293 cells overexpressing MBP (CNTRL), wild-type or mutant 
TUT4/7 and MOV10. Statistical tests were performed as in panel C. No statistically 
significant changes were observed. 
(G) Uridylation of control mRNAs: ACTB, GAPDH, PABPC4 and SOGA2 (as 
indicated) in HEK293 cells depleted of TUT4 and TUT7 or TUT1 (as indicated). 
Statistical significance was calculated as in panel C and is shown where applicable. 
(H) Distribution of U-tail lengths on reporter L1 mRNAs in HEK293 cells under 
depletion of the indicated proteins. The U-tails were grouped according to the 
number of uridines. Data were normalized to all mRNAs for a given condition. 
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(I) Uridylation of L1 reporter mRNAs in control HEK293 cells (transfected with non-
targeting siRNAs, CNTRL) and in cells depleted of TUT1. 
 
Figure S3 3’ RACE-seq and LEAP products sequencing of the L1 reporters with 
defined 3’ ends, Related to Figure 3 
(A) Graphs showing distribution of total tails’ lengths in 3’ RACE-seq data of L1 
reporters designed to possess at their 3’ ends either of: 19A, 19A3U, 26A, 26A2U, 
26A4U, 26A6U, 26A14U, 7U or 26U. The respective reporters are colour coded as 
indicated. 
(B) Logos representing the 3’ RACE-seq data for the indicated reporters. Shown is 
the CGGC sequence common to all reporters and specific sequences. Probability of 
a given nucleotide and of the position occupancy in general is calculated in bits and 
depicted accordingly. 
(C) Plasmids (24), whose inserts’ sequencing is shown in panel D, were cut with XbaI 
and XhoI Fast digest restriction enzymes, yielding fragments of expected length 
(approximately 130bp). Lanes from left to right correspond to clones 1-24 in the table 
in panel D. A molecular weight ladder was included, with the two fastest migrating 
bands corresponding to 100 and 200bp, respectively.  
(D) Validation of genuine reverse transcription of uridylated L1 mRNAs by L1-ORF2p. 
LEAP products seen in Figure 3D lane 5 were cloned into pJET 1.2 blunt plasmid, 
and single bacterial colonies used for preparation of plasmids. Clones were 
sequenced and the results are summarized in the table. One clone (10) possessed a 
chimeric sequence comprising a short stretch of the L1 reporter plasmid-encoded 
sequence (in italics) followed by the genuine 3’ LEAP adapter sequence. 3 clones 
had a heterogenous sequence cloned (2, 20 and 24), while clone 6 had the expected 
L1 3´end followed by a 0.7Kb long sequence of unknown origin. 
 
Figure S4 Effects of TUT4/7 and MOV10 on L1 mRNA steady-state levels, stability 
and translational competence, Related to Figure 4 
(A) Northern blotting to detect endogenous L1 mRNAs in HEK293 (FLP-IN T-Rex), 
HEK293T, PA-1 and HeLa-HA cells as indicated. Total RNA (lanes 1-4), unbound 
RNA fraction retrieved after selecting for poly(A) (SN, using PolyA Purist MAG from 
Ambion; lanes 5-8) and poly(A) RNA (lanes 10-13). The amount of RNA loaded is 
indicated (g). The same blot was re-probed for GAPDH and stained with methylene 
blue prior to any probing, and results are shown below (i.e., loading controls). 
Substantial fraction of unbound L1 mRNAs likely represents oligouridylated or 
truncated mRNAs. 
(B) Confocal microscopy pictures (maximal projections in z) showing mostly 
cytoplasmic localisation of L1-ORF1p-FLAG (stained with rabbit anti-Flag monoclonal 
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antibodies and secondary Alexa-488 coupled antibodies) and of endogenous TUT4 
and MOV10 proteins. 
(C) Rapid cell fractionation following the protocol described by Suzuki et al. (2010) 
and subsequent western blotting to assess subcellular localization of TUT7, TUT4, 
MOV10 in PA-1 cells. Blotting for cytoplasmic (tubulin) and nuclear (histone H4) 
markers were also performed. W – whole cell, C – cytoplasmic compartment, N – 
nuclei. An asterisk denotes an unspecific band. 
(D) Western blot analysis of proteins in PA-1 cells after siRNA-mediated depletion of 
TUT4 and TUT7 or MOV10, as indicated at the top of the panel. CNTRL denotes 
non-targeting siRNAs. A total of 30% (2x) and 5% of the control sample were loaded 
as indicated at the top, to assess depletion efficiency. Blots were probed with rabbit 
polyclonal antibodies as indicated on the left. GAPDH was used as a loading control. 
Superfluous lanes irrelevant to the study were removed (indicated with the black line). 
(E) Western blot validation of overexpression (upper panel) and knock-down (lower 
panel) in HEK293 (FLP-IN T-Rex) cells used for RNA-seq experiments to analyse 
endogenous L1 mRNA steady-state levels. Cells (triplicates) were split for RNA 
isolation and western blots. Blots were probed with rabbit polyclonal antibodies for 
the detection of MOV10, TUT7, TUT4, GAPDH and actin. The latter two proteins 
were used as loading controls. Different volumes of lysates were loaded to help 
assess overexpression and depletion efficiencies. Samples and loading volumes are 
indicated. 
(F) RNA-seq-based estimation of endogenous L1 expression in PA-1 cells transiently 
depleted of TUT4 and TUT7, MOV10 or all three proteins as indicated, using siRNAs 
(see panel D). Uniquely mapped reads for 76 Homo sapiens-specific L1s were 
calculated and normalized to respective controls as indicated. None of the observed 
changes is statistically significant. 
(G, H, I) Estimation of endogenous L1 Ta mRNAs by RT-qPCR using probes as 
described in Coufal, et al., 2009, in PA-1 (G), and HEK293 FLP-IN T-Rex stable cell 
lines (in which indicated proteins were overexpressed by addition of tetracycline, and 
normalised to cells without tetracycline; H) or in HEK293 FLP-In T-Rex cells depleted 
of the indicated protein/s (I). Three to six biological replicates including those used in 
the RNA-seq were analyzed. 
(J) Plasmid JM101/L1.3-O1EGFP-O2mcherry contains a full-length L1 L1.3 
(Sassaman, et al., 1997) element producing L1-ORF1p-EGFP and L1-ORF2p-
mCherry. Additionally, the plasmid contains the mneoI cassette (Moran et al., 1996) 
to monitor retrotransposition. 
(K) A retrotransposition test with the JM101/L1.3-O1EGFP-O2mcherry and parental 
JM101/L1.3. Addition of both fluorescent proteins in L1 ORFs does not severely 
compromise its retrotransposition potential. 
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(L) and (M) HEK293T cells were co-transfected with JM101/L1.3-O1EGFP-
O2mcherry and plasmids overexpressing the indicated TUTases or MOV10. The 
percentage of cells expressing L1-ORF1p-EGFP (L) and L1-ORF2p-mCherry (M) 
were estimated in the total cell populations using FC. Normalized values from 8 
biological replicates (3 independent experiments) are shown. Statistical significances 
were calculated using one-way ANOVA and Tukey’s multiple comparison test (*** 
p<0.001, ** p<0.01, comparison to MBP). 
(N) Plasmids of the pZW-L1RP series containing a full-length L1 (L1RP, Kimberland, 
et al., 1999) element in a modified pcDNA5 FRT/TO backbone producing L1-ORF1p 
and L1-ORF2p with either an epitope FLAG tag or fluorescent EGFP or mCherry tags 
as indicated. All but pZW-L1RP-O2G were produced without or with the megfpI L1 
retrotransposition reporter cassette.  
(O) Retrotransposition test with pZW-L1RP-O1F-megfpI and pZW-L1RP-O1mCh-
megfpI reporters. The presence of either tag does not prevent L1 retrotransposition. 
(P) Translation of L1-ORF1p-mCherry encoded in pZW-L1RP-O1mCh plasmid. Cells 
expressing mCherry over background levels (HEK293T cells transfected with control 
L1 plasmid not encoding any fluorescent tag) were considered. Median mCherry 
intensity was calculated and used as a measure of L1-ORF1p-mCherry translation. 
The medians and interquartile ranges are shown. Six biological replicates (3 
independent experiments) were analyzed. 
(R) Translation of L1-ORF2p-EGFP encoded on the pZW-L1RP-O2G plasmid was 
estimated as in (P) except for EGFP. Six to nine biological replicates (2 or 3 
independent experiments) were analyzed. 
Statistical significances in (P) and (R) were calculated as in panel (L). 
 
Figure S5 Stable cell line validation and co-IP experiments, Related to Figure 5 
(A) Flow cytometry profiles of parental HEK293 FLP-IN T-Rex (black traces) and 
stable cell lines expressing EGFP-TUT4 or EGFP-TUT7 in the absence of (blue 
traces) or following induction of transgene expression with 100 ng/ml tetracycline 
(green traces). “EGFP+ GATE” denotes the region with cells showing higher EGFP 
fluorescence than ~99.9 % of the control cells that do not express EGFP. The 
histograms were obtained using Flowing software. The table below the histograms 
summarizes the percentage of EGFP+ cells within each experimental population. 
(B) Western blot validation of the EGFP-TUT4-expressing stable cell line. Cells were 
grown for 48 h without tetracycline or with addition of 25, 50 or 100 ng/ml tetracycline 
in the medium. Proteins were separated by SDS-PAGE, followed by transfer to 
nitrocellulose membranes and Ponceau S staining (lower panel) to control for protein 
loading. The upper panel shows results after probing with a TUT4-specific rabbit 
polyclonal antibody. 
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(C) Western blot validation of the EGFP-TUT7-expressing stable cell line as in (B). 
Lanes 1 and 5 are reference lanes with material from the EGFP-TUT4 cell line and 
parental HEK293 FLP-IN T-Rex cells, respectively, to show antibody specificity. An 
asterisk denotes an unspecific band. 
(D) HEK293 FLP-In T-Rex cells were fixed with formaldehyde and stained for 
endogenous TUT4 (upper panel) or TUT7 (lower panel) with rabbit polyclonal 
antibodies and Alexa-488-coupled secondary goat anti-rabbit antibodies. Nuclei were 
visualized by Hoechst DNA staining (cyan). Maximal projection images of z-stacks 
are shown. White bars, 10m 
(E) Single z-slides (epifluorescent – left, and bright field – right) of live cells from 
stable cell lines expressing either EGFP-TUT4 (upper panel) or EGFP-TUT7 (lower 
panel). White bars, 10m 
(F), (G), Rapid cell fractionation following the protocol described by Suzuki et al. 
(2010) and subsequent western blotting to independently assess subcellular 
localization of TUT7, TUT4, MOV10. Blotting for cytoplasmic (tubulins or GAPDH) 
and nuclear (fibrillarin, Rrp6 nuclear exosome complex exoribonuclease) markers 
were also performed. Cells were either parental HEK293 FLP-IN T-Rex (F), or HeLa-
HA used in L1 mneoI reporter assays (G). An asterisk denotes an unspecific band. 
(H) Western blotting of proteins associated with either EGFP-MOV10 or EGFP 
showing blot (left), probing with monoclonal GFP antibody (middle; 1% co-IP), and 
polyclonal anti-TUT7 antibodies (right, 5% co-IP, blot before probing depicted on the 
left). Visible is TUT7 in EGFP-MOV10 co-IP and not in control EGFP co-IP. Some 
cross-reactivity towards overrepresented EGFP-MOV10 but not EGFP can also be 
seen. 
(I) Flow-chart of the workflow of the RNA co-IP with FLAG-TUT7. 
(J) Western blotting showing efficient depletion of MOV10 in HEK293T cells used for 
in vivo UV-crosslinking and co-IP with FLAG-TUT7. Shown are western blotting 
results after probing with polyclonal antibodies against MOV10 and GAPDH (loading 
control). Cells were transfected with: Lane 1 – control non-targeting siRNA then 
plasmids encoding L1 reporter and MBP-TUT7; lane 2 – MOV10 targeting siRNA 
then plasmids encoding L1 reporter and FLAG-TUT7; lane 3 – control non-targeting 
siRNA then plasmids encoding L1 reporter and FLAG-TUT7; lanes 4 and 5 – as in 
lane 3 but 0.5 and 0.2 of the material seen in lane 3 was loaded (control to compare 
with lane 2). 
(K) SDS-PAGE and silver staining of proteins recovered in the MBP- and FLAG-
TUT7 co-IP after in vivo UV-crosslinking. Visible are bands representing FLAG-TUT7 
(lanes 2 and 3) and M2 antibody stripped off the beads (lanes 2-4). Loaded were ca. 
10% recovered material (lanes 2, 4) and ~6% recovered material (lane 3). Lane 1 – 
molecular weight ladder (170 and 55 kDa bands are indicated); lane 2 – IP with MBP-
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TUT7 (control); lane 3 – IP with FLAG-TUT7 from MOV10-depleted cells; lane 4 – IP 
with FLAG-TUT7 from control cells. 
 
Figure S6 MOV10 prevents binding of L1-ORF1p to L1-RNA, Related to Figure 6 
 
(A) A 5’-FAM-labelled RNA was incubated with increasing amounts of recombinant 
L1-ORF1p in the presence of TUT7 WT purified from human cells and UTP (lanes 2-
6). A reaction containing only the RNA (lane 1) was included as a control. Another 
reaction containing the RNA, UTP and WT TUT7 but no L1-ORF1p was also included 
(lane 2). On lanes 3-6, increasing amounts of recombinant L1-ORF1p were added 
(as indicated at the top), changing the molar ratio of L1-ORF1p to the RNA from 0 to 
3-fold. Reactions were stopped, purified and separated by PAGE. 
(B) Quantification of the RNA present in the reactions shown in panel (A). Note that 
the graph contains the results of three independent experiments. Measured values 
were corrected for background, assuming no elongation in the control samples. 
Medians, ranges and individual points are shown. Statistical significances were 
calculated using one-way ANOVA and Tukey’s multiple comparison test (*** p<0.001, 
** p<0.01). 
(C) RNase I footprinting assay. An in vitro transcribed L1-3´UTR RNA was labelled 
randomly by the incorporation of 32P UTP and incubated alone (lane 2), or was 
incubated in the presence of Mg2+ATP (lanes 3-8), without (lanes 3 and 6) or with 
recombinant L1-ORF1p in the indicated molar ratio to RNA (lanes 4, 5 and 7, 8) or 
with MOV10 purified from human cells (lanes 6-8). Note that MOV10 was added prior 
to L1-ORF1p addition. Lanes 1 and 9, alkaline hydrolysis ladders used as RNA 
mobility makers. An arrow points to full length L1 RNA. 
(D) RNase I footprinting assay as in panel C. The in vitro transcribed L1-3´UTR RNA 
(lane 1) was incubated in a buffer supplemented with Mg2+ and with ATP and 
increasing concentrations of L1-ORF1p (lanes 2-4); followed by incubation with 
MOV10 (lanes 5-7); or preceded by incubation with MOV10 (lanes 8-10); or preceded 
by incubation with MOV10 but without ATP (lanes 11-13). Finally, all the samples 
(excluding lane 1) were depleted of Mg2+, subjected to RNase I footprinting, purified 
and separated by denaturing PAGE. Visible is lack of L1-ORF1p displacement in 
lanes 12 and 13 as compared to lanes 9 and 10. Visible is effect of MOV10 addition 
after L1-ORF1p in lanes 6 and 7 that might suggest kinetic competition of MOV10 
and L1-ORF1p in binding to RNA. The arrow points to full length L1 RNA. 
(E) RNase footprinting assay as in panel C but with either wild-type (lanes 2-4) or 
mutant (K530A) MOV10 (lanes 5-7). Visible is increased protection of the RNA in 
mutant MOV10 condition, which suggests less effective competition/removal of L1-
ORF1p of the RNA by the mutant protein. The arrow points to full length L1 RNA. 
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Figure S7 Graphical visualization of the 3' RACE-seq approach, Related to Figure 2 
 
(A) Graphical representation of 3' RACE-seq library preparation and the 
oligonucleotides used. First, the 3' adapter RA3_15N was joined to the 3' end of RNA 
by enzymatic ligation. The adapter has: (i) 5' rApp modification for efficient and 
specific ligation by the truncated T4 RNA ligase 2, (ii) delimiter sequence to be used 
in bioinformatics analyses to exclude RT and PCR artifacts (CTGAC, highlighted in 
violet), (iii) unique 15N barcode for individual transcript barcoding (highlighted in 
green), (iv) anchor sequence to pair with the reverse transcription primer (underlined) 
and (v) dideoxyC on the 3' end to prevent concatamer formation. The RNA ligated to 
the adapter sequence was purified from excess adapter and reverse transcription 
was performed with the RT primer, which is compatible with Illumina sequencing and 
has: (i) sequences to base-pair with the adapter (underlined), (ii) 6-nucleotide 
barcode for sample barcoding (highlighted in red), (iii) sequences that base pair with 
the universal outer primer for nested PCR. 
Libraries were generated by nested PCR with 2 outer forward primers (F1 and F2) 
and a single universal reverse primer (uni rev). PCR amplicons of first and second 
PCRs were purified from excess primers on AmPure beads (Agencourt) before 
beginning the next step. 
(B) Flowchart of the bioinformatics approach to 3' RACE-seq data analysis. The 
procedure starts at the top. Data sets are shown in rectangles. Software used is 
depicted in hexagons. 
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STAR Methods 
 
Contact for Reagent and Resource Sharing 
 
Further information and requests for reagents should be directed to Andrzej 
Dziembowski (andrzejd@ibb.waw.pl). 
 
Experimental Model and Subject Details 
We use standard procedures to derivate and cultivate all cell types used in this study 
(see below for a detailed description of these methods). Absence of Mycoplasma spp. 
was confirmed at least once a month and STR-genotyping was used to control the 
identity of the cell lines (Lorgen, Spain). 
 
HEK 293 FLP-IN T-Rex and HEK 293T cells 
HEK 293 cells were derived from a female. 
HEK 293 FLP-In T-Rex cells were purchased from Invitrogen. 
The cells were cultured in monolayers in Dulbecco’s modified Eagle’s medium 
(DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS w/o tetracycline, 
Gibco) at 37 °C in a 5% CO2 incubator. 
 
HeLa-HA and PA-1 cells 
HeLa-HA and human embryonic carcinoma PA-1 were derived from females. 
The cells were cultured in monolayers in minimal essential medium (MEM, Gibco) 
supplemented with L-glutamine and 10% heat-inactivated fetal bovine serum (FBS, 
Gibco) at 37 °C in a 5% CO2 incubator. 
 
Human foreskin fibroblasts 
Human foreskin fibroblasts (HFFs, passage 3-10, from ATCC) were only used to 
generate Conditioned Media (CM). HFFs were grown following the provider’s 
instructions in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 
25 mM HEPES, 2 mM L-glutamine and 10% heat-inactivated FBS.  
 
H9-human embryonic stem cells (hESCs) 
WA09/H9 hESC are female cells. The cell line was obtained from Wicell and was 
maintained in HFF-conditioned media (HFF-CM) using Matrigel-coated plates as 
described (Garcia-Perez et al., 2007, Macia et al., 2017). To prepare HFF-CM, HFFs 
inactivated by γ-irradiation with 3000-3200 rads, seeded in T225 flasks (3x106 
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cells/flask) and cultured in hESC media for 24h (DMEM KnockOut supplemented with 
4 ng/ml β-FGF, 20% Knockout serum replacement, 1 mM L-Glutamine, 0.1 mM -
mercaptoethanol and 0.1 mM non-essential amino acids). HFF-CM was collected and 
frozen until used, and we harvested HFF-CM during seven consecutive days. HESCs 
were passaged manually using a cell-scraper as described (Garcia-Perez et al., 2007, 
Macia et al., 2017). 
HESC-NPCs were cultured in KnockOut DMEM/F-12 with Stem Pro Neural 
Supplement, 1 mM L-Glutamine and Penicillin-Streptomycin (10,000 U/mL). All the 
cell lines were grown in a humidified 7% CO2 incubator at 37ºC. 
 
HESC-derived Neuronal Progenitor Cells (NPCs) 
To differentiate hESCs to NPCs, H9-hESCs were initially cultured for 2 days in N2 
media (DMEM/F12 + N2 supplement (Invitrogen)) containing 10 μm SB-431542 
(Sigma) and 1 μm dorsomorphin (Calbiochem). After 2 days, hESCs were collected 
from plates using a cell-scraper. To generate embryoid bodies (EBs), hESCs were 
seeded in low-attachment plates using N2 media containing 10 μm SB-431542 
(Sigma) and 1 μm dorsomorphin (Calbiochem). EBs were cultured for 4-6 days, with 
daily changes of media. Next, EBs were plated in Matrigel-coated plates (60-mm 
plates) and cultured during 5-7 days on NB medium (0.5x N2, Invitrogen; 0.5x B-27, 
Invitrogen; 20 ng/ml FGF-2, Miltenyi Biotec and 1% penicillin-streptomycin), replacing 
media every other day. After 5-7 days, neuronal rosettes were manually collected, 
dissociated and plated on poly-L-ornithine (Sigma)/laminin (Invitrogen) coated plates 
using NB medium. Upon reaching confluence, NPCs were detached from plates 
using StemPro Accutase Cell Dissociation Reagent (Invitrogen), passaging in a 1:3 
ratio. NPCs were grown for <10 passages. 
 
Mouse testes 
Testes were isolated from 4 P10 young wild-type C57BL/6 mice. The mice were 
maintained according to national regulations. 
 
Method Details 
Cloning 
Plasmids for TUT4/7, MOV10 and other TENTs overexpression 
The pcDNA5 FRT/TO-derived plasmids used in this study were generally named 
using pZW as a prefix with respective tag and protein names specified. Generation of 
pZW-EGFP-ZCCHC6, pZW-EGFP-ZCCHC11, pZW-EGFP-ZCCHC6_D1060A, pZW-
EGFP-ZCCHC11_D1011A plasmids for establishing stable cell lines expressing N-
terminally EGFP-tagged TUT4 (ZCCHC11) or TUT7 (ZCCHC6) or their catalytically 
inactive mutant versions was described in Labno et al., (2016). For the sake of this 
study following plasmids were prepared: pZW-EGFP-MOV10, pZW-EGFP-
MOV10_K530A, pZW-EGFP-MOV10_D645N, pZW-FLAG-TUT7, pZW-FLAG-
TUT7_D1060A, pZW-MBP-TUT4, pZW-MBP-TUT4_D1011A, pZW-MBP-TUT7, 
pZW-MBP-TUT7_D1060A, pZW-mCherry-MOV10, pZW-mCherry-TUT4, pZW-
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mCherry-TUT4_D1011A, pZW-mCherry-TUT7, pZW-mCherry-TUT7_D1060A. Other 
plasmids used in the study were plasmids for overexpression of C-terminally FLAG-
tagged U6 TUTase, PAPD5, GLD2, FAM46C. All plasmids were generated using 
SLIC (Li and Elledge, 2012) and methods described in details in Szczesny et al., 
2018. 
 
3' homonucleotide tracts in L1 megfpI reporters 
An L1RP element lacking its 5 'UTR and containing the megfpI retrotransposition 
indicator cassette was recloned as an entire fragment from plasmid 99 PUR RPS 
EGFP (Ostertag et al., 2000) into plasmid pZW-HSVTKpA (comprising the universal 
Multi Cloning Site of pKK (see Szczesny et al., 2018), a puromycin resistance gene 
(PAC) instead of the original hygromycin gene, and a HSV polyadenylation site 
instead of the original bGH polyadenylation site) by PCR amplification using the 
forward primer ORF1f2 (cagcctccggactctagcgtttaaacttaagcttatggggaaaaaacagaacag) 
and reverse primer LINE-1rep_NheI 
(atcaccctgaaaatacaaattctcgctagcttatactctaagttttagggtacatgtg) and Sequence and 
Ligation Independent Cloning (SLIC) into AgeI and NheI sites to yield the pZW-L1RP-
megfpI-HSVTKpA plasmid. This plasmid was then cleaved with SrfI (New England 
Biolabs) and NotI FD (Thermo Fisher Scientific) restriction enzymes, followed by 
dephosphorylation with FastAP (Thermo Fisher Scientific). 
 
Synthetic long DNA comprising part of the SrfI site, the desired 3' L1 end sequence, 
a sequence encoding a full tRNA-like element cleavable at its 5' end by endogenous 
RNase P (see Doucet et al., 2015) and part of the NotI site were ordered from IDT:  
xyz_for 
GGGC(xyz)GACGCTGGTGGCTGGCACTCCTGGTTTCCAGGACGGGGTTCAAGT
CCCTGCGGTGTCTGC 
xyz_rev 
GGCCGCAGACACCGCAGGGACTTGAACCCCGTCCTGGAAACCAGGAGTGCCA
GCCACCAGCGTC(zyx)GCCC 
 
Where (xyz) in the forward primer specifies either of: 19A, 19A1U, 19A3U, 26A, 
26A1U, 26A2U, 26A3U, 26A4U, 26A5U, 26A6U, 26A14U, 26A26U, 40A, 40A1U, 
40A2U, 7U, 26U and where (zyx) in the reverse primer specifies a complementary 
sequence. 
In case of the “no tail” reporter there was no additional sequence in the place of (xyz) 
and (zyx) in the respective forward and reverse primers. 
 
The primers were either ordered with a 5’ phosphate or phosphorylated using PNK 
(NEB) and annealed after pooling the respective pairs in PNK reaction buffers at a 
1:1 ratio (10 pmol each; 20l total volume) and addition of water to a volume of 
100 μl followed by heating to 95 °C for 10 min (simultaneous enzyme deactivation), 
75 °C for 2 min, 55 °C for 2 min and cooling to RT. 
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Following this step, the annealed oligonucleotides were combined with the SrfI/NotI- 
cleaved dephosphorylated plasmid and ligated for 1h at 22 °C using T4 DNA ligase 
(NEB). 
The resulting plasmids were named pZW-L1RP-megfpI-xyz-TRL, where xyz indicates 
the precise end of each L1 mRNA, and are listed in the Key Resources Table. 
Plasmids were produced from 100 ml MH1 E. coli cultures using a Plasmid Midi kit 
(A&A Biotechnology), sequenced and validated. 
 
Tagging L1-ORF1p with FLAG 
Two DNA fragments were amplified using the 99 PUR RPS EGFP plasmid as a 
template. The 5' fragment encompassed the L1-ORF1p CDS without the 5' UTR and 
a sequence encoding the FLAG tag attached directly to L1-ORF1p lacking the stop 
codon, which was moved to the end of the FLAG tag. The 3' fragment encompassed 
the FLAG-stop codon-linker-ORF2 CDS with or without the megfpI reporter cassette. 
The 5' fragment primers were: forward primer ORF1f2 
(cagcctccggactctagcgtttaaacttaagcttatggggaaaaaacagaacag), reverse primer 
SOPO1Fr1 (ttacttgtcatcgtcatccttgtaatccattttggcatgattttgcagc). 3' fragment primers: 
forward primer SOPO1Ff2 
(gattacaaggatgacgatgacaagtaaagaccatcaagactaggaagaaac), reverse primer for L1 
w/o reporter SOPO21r2 (cagcgggtttaaacgggccctctagactcgagtacatgtgccatgctggtg) and 
reverse primer for L1 with megfpI reporter SOPO21r3 
(cagcgggtttaaacgggccctctagactcgagattatactctaagttttagggtac). The 5' and 3' fragments 
were combined in ~1:1 molar ratios and used in a splice PCR with the 5' and 3' outer 
primers. Finally, the purified splice PCR product was inserted into the HindIII and 
XhoI sites of pKK-NoTag (Szczesny et al., 2018) by SLIC. The plasmids pZW-L1-
O1F and pZW-L1-O1F-megfpI were prepared from 100 ml bacterial cultures, the 
inserts were sequenced and retrotranspositional competence was validated. 
 
Tagging L1-ORF1p with mCherry 
Tagging was accomplished as described above for pZW-L1RP-O1F, but the mCherry 
reference sequence and L1-ORF1p CDS were first amplified and used in splice PCR 
to create a joint L1-ORF1p-mCherry 5' fragment. This fragment was then combined 
with either of the 3' fragments (i.e., lacking or carrying the megfpI reporter cassette 
sequence) and used in splice PCR. The insert was cloned between the HindIII and 
XhoI sites of the pZW-HSVTKpA plasmid. 
Primers used to produce the mCherry fragment were: 
Forward ORF1_mCherry_for (ctgcaaaatcatgccaaaatgaagcttatggtgagcaagggcgagg) 
Reverse ORF1_mCherry_rev (gatgcagtttcttcctagtcttgatggtctctacttgtacagctcgtcc) 
Additionally, for ORF1 CDS amplification, the ORF1 reverse primer 
ORF1_mChtag_rev (cataagcttcattttggcatgattttgcag) was used instead of SOPO1Fr1. 
For Linker-ORF2 CDS amplification (both without and with megfpI), the forward 
primer L1_linker_for (agaccatcaagactaggaagaaactgcatc) was used instead of 
SOPO1Ff2. 
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Plasmids pZW-L1RP-O1mCh and pZW-L1-O1mCh-megfpI were prepared from 
100 ml bacterial cultures, the inserts were sequenced and we next demonstrated that 
these constructs retain their retrotransposition potential in cultured cells. 
 
Tagging L1-ORF2p with EGFP 
Tagging was accomplished by recloning LINE-1 RPS from the 99 PUR RPS EGFP 
plasmid into pKK-TEV-mEGFP linearized with BstHI (AgeI) and NheI restriction 
enzymes using described protocols (Szczesny et al., 2018). 
Primers used to PCR amplify a single insert encompassing the LINE-1 RPS (without 
the 5' UTR and the megfpI retrotransposition indicator cassette) were: forward 
L1Orf1f (tccgaaaacctgtacttccaaggaaccggtatggggaaaaaacagaacag) and reverse L1r-
Stp (atcaccctgaaaatacaaattctcgctagcattcccacctatgagtgagaatat).The obtained plasmid 
pZW-L1RP-O2-G was prepared from 100 ml bacterial culture, and the insert was 
then sequenced and validated. 
 
Tagging both L1 ORFs with EGFP and mCherry 
To generate plasmid JM101/L1.3-O1EGFP-O2cherry, we used a cloning strategy 
very similar to the one described above (available upon request). The final construct 
was fully sequenced. The vector includes an mneoI retrotransposition indicator 
cassette, which allowed us to demonstrate that tagging both L1-encoded proteins 
with fluorescent proteins does not significantly affect retrotransposition efficiency in 
cultured cells. 
 
Stable cell lines – generation and validation 
Related to Figure 5 and Figure S5. Stable cell lines were generated using human 
HEK293 FLP-In T-Rex cells (Invitrogen) and the FLP-In T-Rex system (Invitrogen). 
The cells were seeded in 6-well plates (Greiner) at 0.5x106 cells per well. On the 
following day (20h post seeding), the medium was replaced and cells in a single 
well were transfected with 1.8 μg pOG44 plasmid and 0.2 μg pZW plasmid encoding 
either of the N-terminally EGFP-tagged human TUT4, TUT7, MOV10 or TUT4/7 
mutant versions encoding catalytically inactive proteins using 5 μl Lipofectamine 
2000 (ThermoFisher Scientific). At ~24h post-transfection the cells were trypsinized 
and seeded onto 60-mm dishes (Greiner) in medium supplemented with 50 μg/ml 
hygromycin (Invitrogen). Cells were selected for 12-18 days and the medium was 
exchanged every 2-3 days. No further clonal selection was performed.  
Tetracycline-inducible expression of EGFP was tested using titration of tetracycline 
from 25 to 100 ng/ml in 6-well plates. The cells were harvested and lysed, with the 
lysates used for western blotting (see below) with anti-GFP and anti-ZCCHC11, 
ZCCHC6 or MOV10 antibodies. The cells were also analyzed by flow cytometry. Prior 
to analysis, the cells were detached from the plates by trypsinization, followed by 
addition of media and centrifugation at 350 rcf for 3 min. The medium was removed 
and the cells were suspended in 1 ml PBS. EGFP signals were measured using a 
FACScalibur instrument (BD Biosciences) and the data were analyzed using Flowing 
software (http://flowingsoftware.btk.fi/) or Cyflogic software (CyFlo, Ltd.). 
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Maximal expression of the EGFP-tagged proteins was observed with ≥25 ng/ml 
tetracycline. 
 
Cell compartment fractionation 
Related to Figures S4C, S5F,G. Cells (HEK293, HeLa and PA-1) were fractionated 
into cytoplasmic and nuclear compartments using the REAP fractionation method 
described by Suzuki et al., 2010.  
Related to Figure 2I. To separate cytoplasmic and nuclear RNA, we used 200 μl 1x 
PBS, 0.1% Igepal CA-630, 5 mM EDTA to extract cytoplasmic RNA, after which the 
nuclei were pelleted by 10 sec centrifugation at 5000 rcf and 200 l of the 
cytoplasmic fraction (supernanant) taken for RNA isolation. Nuclear pellet was 
resuspended and washed and pelleted twice with additional 200 μl of the buffer. The 
nuclei were then pelleted and resuspended once again in the buffer. The 200 μl 
fractions were used for RNA extraction with 1 ml TRI-reagent (Sigma) according to 
the manufacturer’s recommendations. 
 
Western blotting 
Cells from a single well of a 6-well plate were detached with PBS (HEK293) or 
trypsinized (HeLa, PA-1) and pelleted by centrifugation at 350 rcf for 3 min. Cells 
were lysed by pipetting the entire pellet 10-20 times in 30 μl 0.5x PBS/0.15% NP40 
supplemented with protease inhibitors as well as viscolase, a DNA and RNA 
nuclease (A&A Biotechnology), added to 0.1 U/μl. The mixtures were incubated at 
37 °C for 15 min with occasional shaking to allow digestion of nucleic acids before 
20 μl 3x SDS-PAGE loading buffer with 30 mM DTT was added. The mixture was 
then boiled and loaded onto 10% SDS-PAGE gels. 
After SDS-PAGE, the proteins were transferred to Protran nitrocellulose membranes 
(GE Healthcare) by wet transfer at 40 V 300 mA for 2h at 4 °C in 1x transfer buffer 
(25 mM Tris-HCl, pH 7.5, 192 mM glycine, 0.1% SDS, 20% methanol). 
Membranes were stained with 0.3% w/v ponceau S in 3% v/v acetic acid, and the 
staining pattern was digitized. The ponceau S stain was removed and membranes 
were incubated with 4% w/v skim milk in TBST20 buffer followed by incubation with 
specific primary antibodies (see Resources table) diluted 1:1,000 (TUTases, FLAG) 
or 1:2,500 (MOV10, GAPDH, tubulins, EGFP, PABP) at 10 °C for 14-20 h. 
Membranes were washed 3 times for 20 min each in TBST20, and then incubated 
with HRP-coupled secondary antibodies (anti-rabbit or anti-mouse; Jackson 
Bioscience) at 1:5000 to 1:30000 (depending on the expected amount of protein) in 4% 
skim milk in TBST20. The membranes were washed 4 times for 20 min each with 
TBST20 and the proteins were detected using an ECL kit (Bio-Rad). The ECL signals 
were digitized with a CCD camera (Alpha Innotech) or exposed to films (CL-Exposure, 
Thermo Scientific) and developed in AGFA Curix CP-1000 device. 
 
Co-immunoprecipitation 
Warkocki et al. 
40 
Related to Figure 5 and Tables S5, S6, S7. HEK 293 FLP-In T-Rex cells stably 
expressing EGFP (control), EGFP-TUT4, EGFP-TUT7 or EGFP-MOV10 cultured for 
7-10 days in the absence of tetracycline. Between 40 and 48h before harvesting, the 
cells were plated onto four 145 mm dishes (Greiner Bioone) in medium containing 
25-100 ng/ml tetracycline. After 40-48h the medium was removed and the cells were 
gently washed twice with room-temperature PBS. Thereafter, dithiobis (succinimidyl 
propionate) (DSP, Pierce) freshly prepared in DMSO was diluted in room-
temperature PBS to 2 mM in 10 ml and overlaid onto the cells. Cells were incubated 
with PBS/DSP for 30-45 min at ~10 °C prior to removing the solution and harvesting 
the cells by scraping (with rapid buffer flow from a 5 ml pipette tip) into ice-cold 100 
mM Tris-HCl (pH 8.0)/PBS (to stop DSP primary-amine reactivity) and centrifugation 
at 500 rcf for 5 min in 50 ml tubes (BD). The cell pellets were either processed 
directly or flash frozen in liquid nitrogen and stored at -80 °C. 
Prior to analysis, the cells were suspended and lysed in 2.5 ml 1x lysis and binding 
buffer (20 mM HEPES-KOH, pH 7.1, 100 mM NaCl, 0.5% Igepal CA-630 (NP40), 
3 mM MgCl2, 10% glycerol, with 2 mM benzamidine, 0.6 μM leupeptin, 2 mM 
pepstatin A and 1 mM PMSF as protease inhibitors and 0.1 mg/ml RNase A) for 
30 min on ice before sonication. Crude lysates were centrifuged at 16,000 rcf at 4 °C 
for 15 min in low protein-binding siliconized tubes (Eppendorf or Sigma). Cleared 
lysates were mixed with ~100 μl magnetic beads coupled with GFP-Trap nanobody 
and incubated at ~10 °C for 1h with head-over-tail rotation. The lysates with unbound 
proteins were removed and the beads with bound proteins were washed 6 times with 
1x washing buffer (as for 1x lysis and binding buffer but with 0.5 M NaCl). The 
proteins retained on the beads were released by boiling with 120 μl release buffer (3% 
SDS, 50 mM Tris-HCl pH 8.0, 50 mM DTT, 10% glycerol) for 5 min. Part (1/10) of the 
material was analyzed by SDS-PAGE and silver staining and the remainder was 
precipitated using methanol-chloroform and analyzed by LC-MS/MS (see below). 
Related to Table S5. ORF1-FLAG pull-downs were done using HEK 293 FLP-IN T-
Rex cells with tetracycline-inducible expression of full-length LINE-1 LcRPS with 
ORF1-FLAG. The co-IP was done as described above. 
 
LC-MS/MS 
Proteins were dissolved in 100 μl 100 mM ammonium bicarbonate buffer, reduced in 
100 mM DTT for 30 min at 57 °C, alkylated in 55 mM iodoacetamide for 40 min at RT 
in the dark and digested overnight with 10 ng/ml trypsin (V5280, Promega) at 37 °C. 
To stop the digestion, trifluoroacetic acid was added at a final concentration of 0.1%. 
The mixture was centrifuged at 14,000 rcf at 4 °C for 20 min to remove precipitated 
material. MS analysis was performed by LC-MS in the Laboratory of Mass 
Spectrometry (IBB 334 PAS, Warsaw) using a nanoAcquity UPLC system (Waters) 
coupled to a LTQ-Orbitrap Velos or QExactive mass spectrometer (Thermo Fisher 
Scientific). The mass spectrometer was operated in the data-dependent MS2 mode, 
and data were acquired in the m/z range of 300-2,000. Peptides were separated by a 
180 min linear gradient of 95% solution A (0.1% formic acid in water) to 35% solution 
B (0.1% formic acid in acetonitrile). Each sample measurement was preceded by 
three washing runs to avoid cross-contamination. 
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UV-crosslink of LINE-1 mRNA to FLAG-TUT7 
Related to Figures 5E, F and S5 I-K. 8x106 293T cells were seeded onto 6 145-mm 
culture dishes. Next day the cells (each dish) were transfected with 300 pmoles non-
targeting control siRNA (stealth siRNA, Invitrogen) or MOV10-targeting siRNA (C; in 
the Key Resources Table) using 60 μl Lipofectamine RNAiMAX (Invitrogen) in 5 ml 
OPTI-MEM (Gibco; to 20ml medium). Next day, cells were trypsinized and 10x106 
cells of each condition were placed onto 2 new 145-mm dishes. Next day, to 
overexpress LINE-1 and TUT7 the cells (each dish) were transfected with 15 μg 
pZW-L1RP-megfpI and 15 μg either pZW-MBP-TUT7 (control) or pZW-FLAG-TUT7 
using 60 μl Lipofectamine2000 (Invitrogen) in 5 ml OPTI-MEM (Gibco; to 20ml 
medium). Cells were allowed to propagate for ~36-40h followed by media removal, 
careful washing of the cells attached to the dish with 2x 18 ml PBS (room 
temperature). Thereafter, cells were overlaid with 5 ml PBS and placed on a tray with 
ice and water. Cells were irradiated with 4x 120 mJ/cm2 in a UV crosslinker (UVP), 
with 1 min intervals between individual crosslinking sessions. Harvested cells were 
pelleted and placed in ice, followed by IP or flash freezing in liquid nitrogen and 
storage at -80°C. 
 
Protein G Dynabeads preparation 
50 μl beads (bed volume; 1.5 mg; per cells’ aliquot obtained from 145-mm dish) were 
washed 2x in 1ml PBS/0.1% Tween20. Thereafter the beads were suspended in 
50 μl PBS/Tween plus 10 μl M2 mouse monoclonal anti-FLAG antibodies (10 μg; 
Sigma), followed by incubation at room temperature for 30-45 min with occasional 
pipetting. The unbound antibody was then removed and the beads washed 2x in 1ml 
PBS/Tween supplemented with 10 ng/ml E. coli tRNA (Roche) for 15min. Finally, the 
beads were suspended in 100 μl PBS/Tween plus 10 ng/ml tRNA and added to clear 
lysates aliquots. Note the beads for all experimental conditions within one 
experimental set were prepared in batch. 
 
IP with FLAG-TUT7 (and MBP-TUT7 as the control) 
The cells (of one 145-mm dish) were lysed in 1 ml Lysis buffer (50 mM Tris-HCl, 8.0; 
50 mM NaCl; 0.5% Igepal CA-630 (NP40 substitute; Sigma); 5 mM EDTA 
supplemented with a protease inhibitors mix) by pipetting 20 times in ice, followed by 
10 min incubation in ice and 5 cycles of sonication (at 4 °C; 30 sec on, 30 sec off; H 
setting in a Diagenode Bioruptor sonicator). Crude lysates were centrifuged at 500 rcf, 
4 °C in 2 ml protein low-bind tubes (Eppendorf). Cleared lysates were mixed with the 
protein G-M2 anti-FLAG antibodies-coupled Dynabeads in protein low-bind tubes, 
followed by head-over-tail rotation at ~6-8 °C for 2h. Thereafter, the lysates (unbound 
material) were removed and the beads were washed 2x with 1ml 1x Lysis buffer, 
followed by 4x in Stringent Washing Buffer (50 mM Tris-HCl, 8.0; 1 M NaCl, 0.1% 
Igepal CA-630; 1.3 M urea; 5 mM EDTA supplemented with a protease inhibitor mix) 
and 2x in Lysis buffer. Each washing was performed for 8-10 min at ~8°C. Washing 
volumes were removed efficiently while beads were gathered on a magnetic stand 
using a vacuum pump with disposable tips. For the last washing the beads were 
transferred to new tubes. Thereafter, enriched proteins and RNAs were released 
from the beads by heating at 80 °C for 3 min twice with 75 μl Release Buffer (2% 
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SDS; 20 mM EDTA; 50 mM Tris-HCl, 8.0; 10 mM DTT; 20% glycerol; 10 ng/ml E. coli 
tRNA). 130 μl were taken for RNA extraction. To uncouple covalently cross-linked 
RNA and protein the mix was supplemented with 20 ng proteinase K (USB) and 
incubated for 30 min at 37 °C followed by standard phenol-chloroform-isoamyl 
alcohol extraction, TURBO DNase treatment and final purification on RNA-specified 
silica columns (A&A Biotechnology). Remaining released materials were treated with 
50U viscolase for 10 min at 37 °C (to uncouple covalently linked RNA and proteins; 
A&A Biotechnology) separated on SDS-PAGE and stained with silver or transferred 
to nitrocellulose membrane (Protran, Amersham) and analyzed by Western blotting 
for MOV10 depletion. 
 
Estimation of LINE-1 and GAPDH mRNA enrichment levels 
All of the retrieved RNA was reverse transcribed with Superscript III (according to the 
manufacturer’s recommendations). The cDNA was used for qPCR with Taq-Man 
probes as described below in the methods applied to estimate steady-state levels 
and stabilities of mRNAs. 
Related to Figure 5E. Enrichment of either LINE-1 or GAPDH mRNA in FLAG-TUT7 
co-IP versus control MBP-TUT7 co-IP (after transfection with non-targeting control 
siRNA) were calculated by using the following formula: 2-(Ct(FLAG-TUT7 co-IP) – Ct(MBP-TUT7 
co-IP)); where Ct is an average Ct of 3 technical qPCR reactions of either LINE-1 
megfpI or GAPDH. 
Related to Figure 5F. LINE-1 and GAPDH levels in FLAG-TUT7 co-IPs from cells 
transfected with either control non-targeting siRNA or siRNA for MOV10 depletion 
were related by using the following formula: 2-(Ct(LINE-1) – Ct(GAPDH)) and normalizing 
median reported for all control co-IPs (without MOV10 depletion) to 1. 
Enrichments were calculated using methods described by Livak and Schmittgen, 
2001. Statistics were calculated using a non-parametric two-tailed Mann-Whitney test 
(GraphPad Prism package). 
 
Retrotransposition assay – megfpI 
Transfection and culture conditions 
Related to Figure 1B. 293T cells were seeded in 6-well plates at 0.3x106 cells per 
well. At ~20h after seeding, cells from a single well in 2 ml medium were transfected 
with 0.75 μg of 99 PUR RPS EGFP (or 99 PUR JM111 EGFP as an internal negative 
control) plasmid and 1.5 μg of pZW plasmids encoding MOV10, TUT4 or TUT7, or 
catalytically inactive mutant versions of TUT4 or TUT7 (all with N-terminal maltose 
binding protein tags, MBP) or only MBP (internal positive control), using 7 μl 
Lipofectamine 2000 (ThermoFisher Scientific) in 300 μl OPTI-MEM (Gibco) per well. 
The next day, the medium was exchanged for medium supplemented with 1 μg/ml 
puromycin (Invitrogen) to select for cells carrying the L1 reporter plasmids. Cells were 
further selected for 3 days. The medium was then exchanged and the cells were 
analyzed by flow cytometry on the following day (4 days post-transfection). LINE-1 
retrotransposition restriction was also observed when TUTases or MOV10 were 
tagged with N-terminal FLAG or mCherry tags. 
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Related to Figure 1C. 293T cells were seeded in 6-well plates at 0.3x106 cells per 
well. At ~20h after seeding, cells in a single well in 2 ml medium were transfected 
with 1 μg 99 PUR RPS EGFP (or 99 PUR JM111 EGFP for negative controls) LINE-1 
retrotransposition reporter plasmids and 50 pmol (in total) siRNAs targeting TUT4, 
TUT7, MOV10 or U6 TUT mRNAs or control non-targeting siRNA (high GC content 
control siRNA from Invitrogen) as described above. Cells were selected for 3 days. 
The medium was exchanged for medium lacking puromycin and the cells were 
analyzed by flow-cytometry 4 days post-transfection. 
Duplicate to triplicate transfections were performed for each condition in a single 
experiment. Two or three experiments included up to at least 6 biological replicates. 
We generally observed 1-4% of EGFP-positive cells in the control conditions (MBP). 
We did not find selection with puromycin critical however it prevented excessive 
proliferation of cells within the 4 days between transfection and FC analysis. 
Related to Figure 3B. 293T cells were seeded in 12-well plates at ~100-150x103 cells 
per well. Next day, the cells were transfected with 0.5g pZW-L1RP-x reporters 
(where x specifies the pre-designed 3’ end) using 3 l Lipofectamine 2000 
(ThermoFisher Scientific) in 200l OPTI-MEM (Gibco). Retrotransposition was 
allowed to occur for ~80h followed by FC analysis as described above. Selection of 
cells was not carried out. On average 2-4% cells transfected with th 26A reporter 
were EGFP positive at the day of analysis. 
 
Flow cytometry – retrotransposition assays 
Cells were detached from the wells of the multiwell plates by trypsinization and were 
suspended in medium containing FBS to stop trypsin activity before centrifugation at 
350 rcf for 3 min. The medium was removed and the cells were suspended in 1 ml 
PBS. EGFP signals were measured using an Attune NxT instrument (Thermo Fisher 
Scientific) equipped with 488 nm and 561 nm light beams. The data were analyzed 
using software provided with the instrument. To gate EGFP+ cells, we first used cells 
transfected with 99 PUR JM111 EGFP containing a mutated LINE-1 (L1-ORF1p, 
R261A/R262A), which abolish retrotransposition (Moran, et al., 1996). The gates 
were adjusted such that 0.025% cells transfected with 99 PUR JM111 EGFP fell 
within the EGFP+ gate. At least 200x103 singlet cells were analyzed for each 
condition. Medians were calculated for all biological replicates and the medians for 
positive control samples were arbitrarily set as 1. Statistical significance was 
calculated using ANOVA and Tukey’s multiple comparison test for all pairs. 
 
Retrotransposition assay – mneoI 
HeLa-HA cells were seeded in 6-well plates at 0.12-0.5x106 cells per well. At ~20h 
after seeding, cells from a single well in 2 ml medium were transfected with 50 pmol 
(in total) siRNA targeting TUT4, TUT7, or MOV10 or control siRNA (high or low GC 
content control siRNA from Invitrogen) using 3-5 μl Lipofectamine RNAiMAX 
(ThermoFisher Scientific) in 300 μl OPTI-MEM (Gibco). On the following day, the 
medium was exchanged and the cells were allowed to propagate for 48h before 
subsequent transfection with 1 μg of either JM101/L1.3 mneoI plasmid or 99 PUR 
RPS EGFP (for negative controls) LINE-1 retrotransposition reporter plasmids. The 
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day after transfection, the medium was exchanged and the cells were allowed to 
propagate for 4 days with a change of medium every 2 days. Thereafter, the cells 
were incubated for 12-18 days with medium supplemented with 600 μg/ml G-418 
(Invitrogen) to select cells in which retrotransposition occurred. The medium was 
exchanged every 2 days. The colonies were stained with crystal violet and counted. 
Six independent experiments were performed (some in duplicates). The number of 
colonies in each experiment and experimental condition was normalized to respective 
controls assuming that the mean retrotransposition rate in the control is 1. 
 
Analyses of L1-ORF1p and L1-ORF2p translation 
Plasmids encoding active LINE-1s: (i) JM101/L1.3-O1EGFP-O2cherry, where L1-
ORF1p has been fused with the EGFP cDNA and where L1-ORF2p has been fused 
with the mCherry cDNA, (ii) pZW-L1RP-O1-mCh encoding ORF1-mCherry and (iii) 
pZW-L1RP-O2-G encoding ORF2-EGFP were used to estimate translation efficiency. 
293T cells were co-transfected with either of the above plasmids and pZW plasmids 
for overexpression of N-terminal tagged proteins as described in “Retrotransposition 
assay – megfpI”. 
Cells were analyzed by flow cytometry 48 h post-transfection. For analyses of L1-
ORF1p and/or L1-ORF2p translation alone, only those cells displaying fluorescent 
signals above that of background levels determined for non-transfected control cells 
were used. Median intensities were calculated for biological replicates and arbitrarily 
set to 1 for MBP-expressing cells (controls). Statistical significance was calculated as 
described in the section "Flow cytometry – retrotransposition assays”. 
 
RNA isolation 
Total RNA was isolated from cells using 1 ml TRI-reagent (Sigma; Chomczynski and 
Sacchi, 1987) per well of 6-well plates according to the manufacturer’s instructions. 
After RNA recovery, the cell pellets were suspended in ~100 μl TNES buffer (50 mM 
Tris-HCl pH 8, 100 mM NaCl, 10 mM EDTA, 1% SDS) supplemented with 20 ng/ml 
proteinase K (USB) and incubated for 15 min at 37 °C to remove contaminating 
proteins. The material was then subjected to two phenol-chloroform extractions. To 
remove DNA contamination, 5-10 μg input RNA used for RNA-seq and 3' RACE-seq 
was additionally treated for 30 min at 37 °C with 2 μl Ambion TURBO DNase 
(ThermoFisher Scientific) in 50 μl. RNA was then purified by either two sequential 
phenol-chloroform extractions or with Clean-Up RNA concentrator silica RNA-binding 
columns (A&A Biotechnology). 
 
Northern blotting 
Cell culture and RNA retrieval 
Related to Figure 4A. 293T cells were seeded in 6-well plates at 0.5x106 cells per 
well. At ~20h post-seeding, cells in a single well in 2 ml medium were transfected 
with 0.75 μg JM101/L1.3 nomarker and 1.5 μg pZW plasmids: empty (p0 described 
as pKK-NoTag in Szczesny et al., 2018), or encoding EGFP, mCherry, MBP, or 
MOV10, TUT4, TUT7 or TUT4 and TUT7 catalytically inactive mutant versions 
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tagged with N-terminal MBP using 7 μl Lipofectamine 2000 (ThermoFisher Scientific) 
in 300 μl OPTI-MEM (Gibco) per single well. At 30h post-transfection, the medium 
was removed and RNA was extracted using 1 ml TRI-reagent per well (as described 
in “RNA isolation”). 
Related to Figure S4A. Total, TURBO DNase (Ambion)-treated RNA from HEK293 
FLP-IN T-Rex, 293T, PA-1 and HeLa-HA cells was used in a poly(A) mRNA selecting 
protocol with the Ambion’s Poly(A)Purist MAG kit according to the manufacturer’s 
recommendations. 
 
RNA separation in denaturing agarose gels 
To visualize long RNA with high resolution, we used the protocol described by 
Mansour and Pestov, 2013. Briefly, RNAs were separated in 15 x 20 cm 1% agarose 
gels with 0.45 M formaldehyde in TT buffer for 4-5h at 70 V until the xylene cyanol 
dye front was within ~0.5 cm of the gel margin. Gel electrophoresis capillary transfer 
to Amersham Hybond N+ nylon positively charged membranes was then immediately 
performed O/N at RT in 20x SSC. The blots were rinsed in water and RNA was fixed 
to the membrane by 254 nm UV crosslinking using a CL-1000 crosslinker (UVP) with 
the auto crosslink function (120 mJ/cm2). The membranes were stained with 
methylene blue and the staining was digitized. The membranes were then 
preincubated in PerfectHyb hybrydization buffer (Sigma) for at least 1h at 65 °C. 
 
Probe production 
We used ssDNA probes randomly labeled with 32P (dATP). For templates, we used 
PCR amplicons generated from the 99 PUR RPS EGFP plasmid as a template and 
the primers L1_seq7 (gatatcatctcacaccagttag) and ORF2_rev1 
(tcaattcccacctatgagtgagaa) to obtain a 497 bp fragment of the ORF2 3' region. The 
PCR amplicon (100 ng) was used in a custom linear amplification using only a single 
primer, SONDA_ORF2 (ctgaggaatcgccacactgacttccac), together wtih 50 μM 
dCTP/dGTP/dTTP and 32P dATP ~1 μM in Phusion HF buffer using Phusion HF 
polymerase (Thermo Scientific). A total of 25 cycles were used to generate a 154 bp 
probe. Analogous probes were prepared for GAPDH using the primers 
GAPDH_qP_f1 (tgttgccatcaatgacccctt) and GAPDH_qP_r2 (gtccaggggtcttactccttg) to 
yield a 930 bp dsDNA fragment and GAPDH_qP_r1 (ctccacgacgtactcagcg) to 
generate the ssDNA probe. 
All probes were separated from template dsDNA and shorter products using 6% 
denaturing PAGE. Full-length probes were cut-out of the gel, eluted and precipitated 
as described in Warkocki et al., 2015. 
 
Hybridization conditions 
Blots were incubated with ~0.5-1x106 cps/ml probes in ~5-10 ml PerfectHyb 
hybridization buffer (Sigma) for 24h at 65 °C with constant head-over-tail rotation. 
Blots were washed 3 times with 0.5x SSC/0.1% SDS for 20 min at 65 °C before 
drying and exposure to Fuji 32P screens. The screens were scanned using a Fuji 
PhosphorImager (FLA7000). 
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RNA-seq 
Cell culture and RNA retrieval 
Triplicate biological samples were prepared for each tested condition. 
HEK293 FLP-In T-Rex cells were cultured (and transfected) in 6-well format as 
decribed above for retrotransposition assays. 
For overexpression conditions: HEK293 FLP-In T-Rex stable cell lines expressing 
EGFP-TUT4, EGFP-TUT7 were cultured for 48h in the presence of 100 ng/ml 
tetracycline or in its absence. Similarly, HEK293 FLP-In T-Rex cells were transfected 
with pZW-EGFP-MOV10 plasmid for MOV10 overexpression and cultured with or 
without tetracycline for ~48h before harvest.  
For depletion conditions in HEK293 FLP-In T-Rex: cells were transfected with 
50 pmoles respective siRNAs using 5 μl Lipofectamine RNAiMAX (Invitrogen) 
according to the manufacturer’s recommendations and cultured for ~68h prior to 
harvesting. 
For depletion conditions in PA-1: cells were transfected with siRNAs as described in 
“Northern blotting”. After 3 days, the cells were trypsinized and transferred into new 
6-well plates at 0.2x106 cells per well, followed by another identical transfection. 
Finally, 6 days after the first siRNA transfection the cells were used to isolate total 
RNA as described above. A portion (1/3 volume in media) of the trypsinized cells was 
used for protein retrieval for western blotting validation of protein depletion. RNA was 
treated with Ambion TURBO DNase (ThermoFisher Scientific) according to the 
manufacturer’s recommendations. 
 
RNA-seq library preparation 
Following DNase treatment, all RNA samples were supplemented with equal 
amounts of ERCC RNA spike-in mix (Thermo Fisher Scientific) followed by depletion 
of rRNA using a Ribo-Zero H/R/M Kit (Epicentre) according to the manufacturer’s 
protocol. Strand-specific RNA libraries were prepared in triplicate using a KAPA 
Stranded RNA-seq Library Preparation Kit for Illumina platforms (KAPA Biosystems) 
according to the manufacturer’s protocol that included RNA fragmentation for 8 min 
at 95 °C and 700 μM adapters for amplification. We used 7 cycles of amplification to 
generate the libraries, which were analyzed by capillary electrophoresis using a 
Bioanalyzer 2100 (Agilent). The libraries contained ~250 bp inserts. 
 
RNA-seq library sequencing 
The libraries were sequenced using an Illumina NextSeq500 sequencing platform to 
an average number of ~20x106 reads per library in the 75-nt paired-end mode. 
Details in the online supporting material. 
 
LINE-1s differential expression 
Reads were mapped against the human genome (ver. hg38) using STAR (Dobin et 
al., 2013) and counted using TEtranscripts (Yin et al., 2015) and –mode unique 
settings, with Gencode v27 basic for gene and hg38_rmsk_TE.gtf downloaded from 
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http://labshare.cshl.edu/shares/mhammelllab/www-data/TEToolkit/ for repetitive 
elements annotation. Differential expression analysis was performed using DESeq2. 
For the purpose of statistical analysis counts for all human-specific LINE1 sequences 
were summed and treated as single. For the purpose of Figures 4F,G and S4F 
experimental samples were normalized to controls using a normalized counts mean 
across all control replicates. 
 
Splint-ligation of long spike-in ssDNA 
In the original TAIL-seq paper (Chang et al., 2014), full-length spike-in sequences 
used in TAIL-seq sequencing for poly(A) length estimation were generated by PCR 
using a long ssDNA template. We prepared spike-ins as described by Cheng et al., 
2014. In this case, however, long-A spike-ins (64 As and to a far lesser extend 32As) 
but not the short-A spike-ins tended to become shortened in PCR. Thus we ordered 
full-length ssDNA spike-ins to avoid amplification. Spike-ins having 0, 8, 16 and 32 
consecutive adenines could be ordered as single synthetic DNAs whereas spike-in 
comprising 64 consecutive adenines could not be synthesized in this way. We thus 
ordered 5' and phosphorylated 3' regions of these spike-in (see Key Resources Table) 
for use in splint ligations. The reaction comprised 200 pmol 5' fragment, 200 pmol 
splint DNA and 300 pmol 3' phosphorylated fragment in 10 mM Tris-HCl pH 8 and 
20 mM NaCl in 33 μl. The reaction was heated to 80 °C for 5 min, slowly cooled to 
RT, and combined with 4 μl and 3 μl T4 DNA ligase buffer and enzyme (NEB), 
respectively. The reaction was incubated at RT (22 °C) for 2h and then mixed with 
formamide loading dye. Ligated full-length ssDNA spike-in were separated from 5' 
and 3' fragments and the splint in 6% denaturing PAGE and purified. The ligation 
efficiency was ~50-70%. 
 
3' RACE-seq 
Cell culture and RNA retrieval 
At least 3 biological replicates were prepared for each tested condition. 
Tests of the effects of either protein overexpression or depletion were performed in 
both HEK293 FLP-In T-Rex cells. The transfection conditions were as described 
above in “Retrotransposition assay – megfpI”. 
PA-1 cells were used to assess the effects of TUTases or MOV10 depletion on LINE-
1 3' ends. Cells were transfected as described above in “RNA-seq”. 
To test genome-encoded LINE-1 mRNA, wild type, unperturbed PA-1, H9 and NPC 
cells were cultured as described above. 
Mouse testis tissue was acquired as described above. 
RNA was isolated as described above. 
 
3' RACE-seq library preparation 
Total RNA acquired from either whole cells or testis or from cytoplasmic and nuclear 
cell compartments was treated with Ambion TURBO DNase (ThermoFisher Scientific) 
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according to the manufacturer’s recommendations and as described above. RNA 
(~2-3 μg) for each sample was used in a ligation reaction containing 125 pmol 
RA3_15N 3’ adapter (5' preadenylated and individually barcoded with a 15N 
sequence). The reactions were carried out in 20 μl with 1x T4 RNA ligase 2 truncated 
buffer (NEB) supplemented with PEG-8000 at 10% final concentration, 0.25 U/μl 
RiboLock inhibitor (Thermo Fisher Scientific), 3 pmol of the 5' FAM-labelled 44-mer 
oligonucleotide RNA44 (Future Synthesis) and 300 U T4 RNA ligase 2 truncated 
(NEB) for 18h at 18 °C. To assess ligation efficiency, 1/10 of the sample was loaded 
onto 10% denaturing PAGE to separate free and RA3_15N-ligated RNA44. The gels 
were scanned using a FLA-7000 apparatus (GE Healthcare). We assessed the 
ligation efficiency of RNA44 and RA3_15N to be at least 80% for all samples. The 
remaining sample was mixed with 18 μl Agencourt AMPure XP magnetic beads 
(Beckman Coulter) and the ligated RNAs were separated from non-ligated adapters 
and short (<100 nt/bp) RNA/DNA fragments according to the manufacturer’s protocol. 
RNA ligated to RA3_15N was released from the beads with 20 μl water. 
The samples were then mixed with 100 pmol RNA PCR Index Primers (Tru-Seq 
Illumina) that each contained a barcode specific for the sample (48 indexes available). 
The primers base-paired with the 3' end of the RA3_15N adapter to preserve the 
individual transcript barcoding (15 degenerate nucleotides). The samples were then 
reverse-transcribed in 20 μl using 200 U (1 μl) Super Script III reverse transcriptase 
(Thermo Fisher Scientific) according to the manufacturer’s protocol. After incubating 
RNA-RA3_15N with the primers and dNTPs (0.2 μM) at 65 °C for 5 min, the samples 
were cooled to 55 °C for 5 min and placed on ice. Buffers were then added, followed 
by addition of SSIII and incubation at 55 °C for 1 min and 45 min at 45 °C. The 
enzymes were then denatured by incubating at 75 °C for 15 min. The cDNAs were 
purified from the excess primers, fragmented RNA and reaction buffers using 
Agencourt AMPure XP beads as described above. 
3' RACE-seq libraries were generated using a nested PCR approach for reporter 
plasmid-encoded and endogenous genome-encoded LINE-1 mRNAs. Libraries for 
GAPDH mRNA were prepared as controls. For each sample, 1/4 of the cDNA was 
used in a 20 μl PCR reaction with mRNA-specific outer primers (L1 primer 
O2_ngsPCR1_for2: gcaagaacaaaaaaccaaacaccg and GAPDH primer GAPDH3R1: 
ctcctcacagttgccatgt) at 0.4 μM and 0.3 μM of a universal reverse primer RPuni 
(CAAGCAGAAGACGGCATACGAGAT; denoted uni rev in Figure S7), which is 
complementary to the extreme 3' region of all RNA PCR Index Primers. Phusion HF 
enzyme and buffers (Thermo Fisher Scientific) were used according to the 
manufacturer’s recommendations. Routinely, 20 PCR cycles were performed with a 
12 s elongation at 70 °C. The PCR1 amplicons were purified from excess unused 
primers, fragmented RNA and reaction buffers using Agencourt AMPure XP beads as 
described above. 
A second PCR (PCR2) was performed using purified products from the first PCR 
(PCR1) as templates in a 25 μl reaction volume. L1- or GAPDH-specific outer 
primers were used as specified in Table S1 at 0.36 μM and RPuni at 0.4 μM. The 
other reaction conditions were as for PCR1. PCR2 products were purified twice using 
Agencourt AMPure XP beads. Following purification, the libraries were eluted in 20 μl 
and quantified using a NanoDrop spectrophotometer (Thermo Fisher Scientific). Most 
of the libraries were within 10-30 ng/μl. The libraries were diluted to 3-5 ng/μl and 
analyzed by capillary electrophoresis using a Bioanalyzer 2100 (Agilent). Most 
libraries were ~280-300 bp long (after subtracting 120 bp adapter sequences). 
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Libraries and spike-in ssDNA sequences (used to estimate poly(A) length, 
synthesized as “ultramers” by IDT) were quantified using qPCR and a Platinum 
qPCR kit (Thermo Fisher Scientific). 
 
3' RACE-seq library sequencing 
3’ RACE-seq libraries were sequenced on Illumina MiSeq, using V3 chemistry, with 
settings forcing storage of raw intensity files (cif files). To overcome the limitation of 
maximum number of individual libraries sequences in single sequencing run we 
pooled libraries targeting different transcripts and restored them in the further 
analysis steps using unique primer sequences. All libraries were sequenced with the 
pair-end settings, with read lengths 300+300 (with the exception of one experiment, 
where 100+150 read lengths were used). Special full-length spike-in ssDNA 
(references for poly(A) length) were included to produce ~150x103 reads per single 
spike-in.  
 
3' RACE-seq library cloning 
Related to Figure S2E. Selected libraries were also cloned into pCR-Blunt II-TOPO 
(Invitrogen) or pJET1.2/blunt (Thermo Fisher Scientific) according to the 
manufacturer’s recommendations. Plasmid mini (A&A Biotechnology) was used for 
plasmid preparation. Clones were digested with enzymes flanking the insert and 
selected clones were sequenced using standard Sanger sequencing. 
 
3’ RACE-seq data analysis 
Graph presenting the flow of the analysis is presented in Figure S7B. Raw 
sequencing data (containing cif intensity files) were processed using tailseeker 3.17 
(https://github.com/hyeshik/tailseeker), to produce fastq output and get information 
about the length of A-tails (and possible additions at the 3’end of the tail). Output files 
were demultiplexed by primer sequences using sabre 
(https://github.com/najoshi/sabre, modified to leave primer sequences from the 
output), allowing maximum 2 mismatches in the primer sequence. Resulting reads 
were then further processed using a set of in-house prepared scripts to get detailed 
information regarding 3’ ends of analyzed transcripts. For libraries targeting LINE1 
reporter (or control transcripts: ACTB, GAPDH, PABPC4 or SOGA2) both 5' (R5 – 
notation based on the tailseeker3 output) as well as 3' (R3) reads were mapped to 
the respective sequences using bowtie2 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322381/, Langmead and Salzberg, 
2012), with –very-sensitive-local setting to allow for soft-clipping of non-templated 
nucleotides. In the case of libraries targeting endogenous LINE1 sequences 
Repeatmasker (Smit, AFA, Hubley, R & Green, P. RepeatMasker Open-4.0. 2013-
2015 <http://www.repeatmasker.org>) was used over both R5 and R3 reads, with 
settings „-norna -nolow -qq -div 10” and human repeats library filtered to contain 
LINE1 sequences only, or mouse specific database in case of murine samples. Part 
of sequences which were not assigned to any LINE1 sequence were treated as non-
templated (clipped) as in the case of reporter LINE1 sequences and extracted for 
further analysis. For all subsequent steps only pairs in which at least one read was 
identified as coming from desired transcript were considered for analysis.  
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Next, we analyzed 3’ end types of tails present in analyzed samples and the rate of 
uridylation. All pairs for which tailseeker identified any tail were included in the 
analysis without any modification. In the other case we used non-templated 
nucleotides to further classify such reads. As we expected short fragments due to 
localization of RACE primers, only reads containing tailseq-delimiter sequence 
CTGAC in non-templated fragment of R5 were considered for analysis. Any 
nucleotides preceding the delimiter were treated as a possible tail. If a non-templated 
fragment didn’t contain any nucleotides before CTGAC such reads were excluded 
from the analysis. In the case of experiment, where R5 read was much shorter (50nt), 
if we were able to locate CTGAC delimiter sequence in R5 non-templated fragment, 
preceding nucleotides were treated as a tail, otherwise sequence clipped from the R3 
read was treated as a possible tail. 
All possible tails were then grouped into classes based on their nucleotide 
composition: (i) A-only tails ii) AU tails (A tail with additional U); (iii) U-only tails; (iv) 
no tail – when no tail was detected and (v) other (no falling into any of mentioned 
classes). The latter were excluded from the analysis as they are possible artifacts of 
the nested PCR protocol used for library generation.  
Uridylation frequency was calculated as fraction of AU and U-only tails compared to 
all classified. 
 
Statistics 
For multiple group comparisons, when normality assumptions were met, we used 
one-way ANOVA and Tukey’s post hoc test.  
 
Assessment of LINE-1 mRNA steady-state levels and stabilities by RT-qPCR 
Estimation of LINE-1 mRNA steady-state levels 
Related to Figure 3B. 293T cells were plated at 120x103 cells per well of a 12-well 
plate. Next day the cells in a single were transfected with 0.5 μg pZW-L1RP-megfpI-
xyz-TRL (where xyz is either of: 19A, 19A3U, 26A, 26A2U, 26A4U, 26A6U, 26A26U, 
7U, 26U) and 3 μl Lipofectamine 2000 (Invitrogen) in 200 μl OPTI-MEM (Gibco). 
Triplicate to quadruplicate transfections were done for a single reporter in a single 
experiment (3 experiments in total). Cells were harvested ~36-40h post-transfection 
and RNA isolated using TRI reagent and as described in the below paragraph. 
Related to Figures 4 and S4. RNA was retrieved as for RNA-seq. Four to six 
biological replicates were analyzed. 
 
Estimation of reporter LINE-1 mRNA stability – transfections and RNA retrieval 
293T cells were plated at 360x103 cells per well of a 6-well plate. Next day the cells 
in a single well were co-transfected with 1 μg pZW-L1RP-megfpI and 1 μg pZW 
plasmid encoding either MBP, MBP-TUT4, MBP-TUT7, MBP-MOV10 (or FLAG-
tagged versions, but TUT4 that does not express well with N’ FLAG) and 6 μl 
Lipofectamine 2000 (Invitrogen). 8h later cells from 1 well of a 6-well plate were 
trypsinized and reseeded onto 6 wells of a 24-well plate. After additional 12h 
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actinomycin D was added in time intervals to expose the cells to the chemical for 6, 4, 
3, 2, 1h and a single well was kept without actinomycin D addition. The medium was 
removed and the cells were covered with 0.5 ml TRI reagent (Sigma). RNA was 
isolated using extraction with chloroform as described in the manufacturer’s 
procedures and additional phenol-chloroform extraction. RNA was measured and 
5 μg treated with 2μl TURBO DNase (Ambion) according to the manufacturer’s 
procedure for 1h. Following enzymatic DNA removal RNA was purified from the 
reaction mixture using Clean-Up RNA Concentrator silica columns (A&A 
Biotechnology), eluted with 40 μl water and concentration estimated by UV 
spectroscopy. Six independent biological replicates were performed.  
 
RT-qPCR 
Reverse transcription of 0.2-1 µg of RNA was performed with SuperScript III 
(Invitrogen) according to the attached protocol and using priming with 50 ng of 
random primers (Invitrogen). Obtained cDNA was subjected to qPCR experiments in 
20x final dilution. Two different approaches were applied. Endogenous LINE1 and 
LINE1 reporter transcripts were detected in TaqMan™ type assay (Applied 
Biosystems, TaqMan™ Fast Advanced Master Mix and primers and probe with FAM 
dye) in one reaction with probes for detection of GAPDH transcripts (Applied 
Biosystems, TaqMan™ Gene Expression Assay, 4448490, probe with VIC dye). 
Custom oligonucleotides sequences were as follows, for detection of LINE1 reporter: 
forward primer TAQMAN_EGFPI_2_FOR (ggtgaacttcaagatccgccac), reverse primer 
TAQMAN_EGFPI_2_REV (gtcgccgatgggggtgtt), probe TAQMAN_EGFPI_2_PROBE: 
(cggccagctgcac). 
For detection of endogenous L1-Ta mRNA primers and probe were adapted from 
Coufal, et al., 2009: forward primer Coufal_for (tgcggagaaataggaacactttt), reverse 
primer Coufal_rev (tgaggaatcgccacactgact), probe Coufal_probe 
(ctgtaaactagttcaaccatt). 
MYC transcripts levels were detected using standard qPCR approach and 
Platinum™ SYBR™ Green qPCR SuperMix-UDG (Invitrogen) with 0.2 µM primers: 
forward primer TTCGCAACTATGTGTTCGCG (U6ChF), reverse primer 
AAAACGGTTCATCCTTATGC (U6ChR). 
Amplification and data acquisition was conducted in LightCycler® 480 (Roche) using 
standard temperature schema and reaction compositions proposed by the qPCR 
reagents manufacturers.  
 
LEAP 
LEAP analysis was performed on the basis of the concept described by Kulpa and 
Moran (2006) with modifications. 
Briefly, three 145-mm dishes were each seeded with 3x106 HEK 293T cells. Fourteen 
hours after seeding, the cells in 25 ml medium were transfected with 14 μg of pZW-
L1-26A-TRL, pZW-L1-26U-TRL or pZW-L1-26A26U-TRL using 60 μl Lipofectamine 
in 5 ml OPTI-MEM (Gibco) as per the manufacturer’s recommendations. Around 40h 
after transfection, the cells reached ~90% confluency and were harvested by 
scraping into PBS and centrifuging at 2,800 rcf for 7 min at 4 °C. The cell pellets 
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were then suspended in 300 μl lysis buffer (0.35x PBS, 6 mM EDTA, 0.12% Igepal 
CA-630) supplemented with EDTA-free protease inhibitors (Roche). The cells were 
lysed by pipetting several times, incubated on ice for 10 min and centrifuged at 
4,000 rcf for 2 min at 4 °C. Then, 300 μl was taken from each sample and centrifuged 
again as described above. About 220 μl was loaded onto a sucrose cushion in 
20 mM Tris-HCl pH 7.5, 80 mM NaCl, 5 mM MgCl2, 1 mM DTT supplemented with 
EDTA-free protease inhibitors at 25 °C (top 250 μl 8% sucrose, bottom 800 μl 17% 
sucrose) in TFT-80.2 tubes and spun at 58,000 rpm for  h at 4 °C in a TFT-80.2 rotor 
(Thermo Fisher Scientific). The transparent to yellowish pellets, ~3 mm in diameter, 
were suspended by pipetting in 160 μl (each) 0.1x PBS, 50% glycerol, 5 mM DTT 
supplemented with EDTA-free protease inhibitors. A portion of this sample was flash 
frozen in liquid nitrogen and stored at -80 °C for RT-PCR. 
Eight reverse transcription reactions in 20 μl that included 1 μl suspended RNPs, 
0.2 μM reverse primer LEAP_12T 
(GCGAGCACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTVN) or 
LEAP_12A (GCGAGCACAGAATTAATACGACTCACTATAGGAAAAAAAAAAAABN), 
0.3 mM dNTPs and buffers provided with the Super Script III reverse transcriptase 
(First Strand buffer, 250 mM Tris-HCl pH 8.3 at RT, 375 mM KCl, 15 mM MgCl2 
supplemented with DTT to 5 mM) were prepared. Reactions were carried out at 
37 °C for 1h followed by protein denaturation at 75 °C for 15 min. The cDNA was 
purified using 1 volume Agencourt AMPure XP beads as described above and eluted 
with 20 μl water. 
The purified cDNA (1 μl) was used in a standard PCR reaction in 25 μl total volume 
with Phusion HF polymerase and buffers (Thermo Fisher Scientific) and 0.2 μM both 
forward L13UTRef primer (GAACTCCATATATGGGCTAT) and LEAP_rev reverse 
primer (GCGAGCACAGAATTAATACGACT). Amplification was performed in 35 
amplification cycles. 10 μl of the reactions were separated in 1% EtBr-agarose gel. 
 
Recombinant protein production 
TUT7 was expressed in FreeStyle 293-F cells (Invitrogen) that were cultured to a 
density of 1 × 106 cells/ml in five 30 ml aliquots of FreeStyle 293 Expression Medium 
(Gibco). The cells were transfected using 90 μg linear PEI at 1 μg/μl (MW= 25,000; 
Polysciences, Inc.) and 30 μg of pZW-EGFP-ZCCHC6 for EGFP-TEV-TUT7 
expression. Following transfection, the cells were cultured for 48h at 37 °C, 5% CO2, 
with constant rocking at 120 rpm. Flow cytometry of a small fraction of the pZW-GZ6-
transfected and non-transfected cells showed that ~25-35% of cells expressed 
eGFP-TUT7 proteins over that of background levels. The cells were then centrifuged 
for 5 min at 500 g and the resulting cell pellet was suspended in 5 ml Buffer 1 (20 mM 
Tris-HCl pH 8, 500 mM NaCl, 0.1% Triton X-100, 100 U viscolase nuclease (A&A 
Biotechnology) and protease inhibitors). The mixture was rotated head-over-tail at 
10 °C for 15 min and then sonicated at 10 °C for 30 min using a Bioruptor sonicator 
(Diagenode) operating in the heavy duty setting with 15 s pulses followed by 45 s 
pauses. The lysate was cleared by centrifugation at 12,000 rcf at 4 °C for 20 min. 
The resulting supernatant was bound to magnetic beads (CNBr-activated SepFast 
Mag4F, Biotoolomics) coupled to an anti-GFP nanobody (home-made) for 2h at 
10 °C with head-over-tail rotation. The beads were then washed with 40 bed volumes 
Buffer 1. TUT7 was released from the beads by TEV protease (home-made) 
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digestion in 300 μl Buffer 1 supplemented with 10 μg TEV protease for 12h. The 
released and bead-retained proteins were analyzed by SDS-PAGE and Coomassie 
Brilliant Blue staining. Aliquots were supplemented with glycerol to 20%, frozen and 
stored at −80 °C. 
MOV10 WT and MOV10 K530A mutant (Gregresen, et al., 2014) were prepared 
similarly to what is decribed above except that an N-terminal MBP tag was used 
(pZW-MBP-MOV10 or pZW-MBP-MOV10_K530A plasmids) and affinity 
chromatography was carried out with amylose resin (NEB). 
L1-ORF1p was produced in Escherichia coli. The full-length ORF1 CDS was 
amplified using the 99 PUR RPS EGFP plasmid as a template and was cloned into 
the pET28 expression vector, with a C-terminal 6xHis tag. The plasmid was then 
transformed into BL21-RIL cells and an aliquot was used to inoculate LB 
supplemented with kanamycin (50 μg/ml) and chloramphenicol (37.5 μg/ml). The 
cells were grown for 12h at 37 °C with constant rocking (150 rpm). An inoculum from 
this culture was then used to start a 1 L culture in an autoinducing medium (AIM-
Formedium) and the culture was continued for 48h at 18 °C with constant rocking. 
The cells were harvested by centrifugation and the cell pellet was suspended in 
150 ml Buffer 1 (20 mM Tris-HCl pH 8, 500 mM NaCl, 10 mM imidazole 
supplemented with protease inhibitors (Roche EDTA-free) and 50 μg/ml lysozyme). 
The cells were lysed with the Emulsiflex for 15 min following the manufacturer’s 
guidelines. The lysate was cleared by centrifugation at 37,000 rpm in a Thermo FL37 
8 × 100 rotor at 4 °C for 45 min. Recombinant ORF1 was bound to a 5 ml NiNTA 
FastFlow column (Qiagen) using Akta Xpress, and the column was washed with 20 
column-volumes of Buffer 1 and two column volumes of Buffer 2 (20 mM Tris-HCl pH 
8, 1 M NaCl). ORF1 was eluted with Buffer 3 (20 mM Tris-HCl pH 8, 500 mM NaCl, 
300 mM imidazole). Aliquots of the collected fractions were analyzed by SDS-PAGE 
and Coomassie Brilliant Blue staining. Those fractions containing ORF1 were diluted 
to produce 100 mM NaCl and underwent a final purification on a RESOURCE Q 
column (GE Healthcare) and gel-filtration on a size-exclusion HiLoad Superdex-200 
column (GE Healthcare). The purified protein was analyzed by SDS-PAGE and the 
concentration was determined using a Nanodrop apparatus at 280 nm and the 
respective molar extinction coefficient. Samples were supplemented with glycerol to 
10%, frozen and stored at -80 °C. 
ScPRP2 was purified as described in Warkocki, et al., 2009, 2015. 
HsSUV3 was purified as described in Pietras, et al., Nat Comm in revision. 
 
In vitro uridylation assays 
With 5’ 32P-labelled RNA, L1-ORF1p, MOV10 and TUT4 
Five pmoles synthetic RNA44 (Future Synthesis) was labelled with 32P at their 5’ end 
in 20 μl by using 6 μl 32P ATP (10 days post the reference date) and PNK (NEB) in 
0.7x NEB2 buffer (home-made) for 30 min at 37 °C. The RNA was purified off 
unincorporated 32P ATP by passing through Sephadex G-50 column and further 
purified by denaturing PAGE in a 6% gel, excised with a single nucleotide resolution, 
eluted in REB (300 mM NaOAc, 5.3; 2 mM EDTA; 0.5% phenol/chloroform/isoamyl 
alcohol 25:24:1) at 4 °C overnight and precipitated. 
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Final concentrations of components in the biochemical in vitro reconstitution 
reactions: RNA44 0.6–1.25 nM, ATP – 0.5 mM, UTP – 0.25 mM, salt (NaCl) 
~130 mM, DTT 1.25 mM, Tris-HCl 8.0 20 mM, MgCl2 2 mM, 
MOV10/HsSUV3/ScPRP2 ~5 nM, TUT4 ~0.25 nM, cold-trap DNA oligo 
(GGGCAAAAAAAAAAAAAAAAAAAAAAAAAA 
GGGGGGGGGGGGGGGGGACGCTGGTGGCTGGCACTCCTGGTTTCCAGGACG
GGGTTCAAGTCCCTGCGGTGTCTGC) ~30 nM. Cold trap was included to prevent 
rebinding of L1-ORF1p to RNA44 after it has been displaced by the MOV10 RNPase 
activity. 
RNA was mixed with ATP, UTP, DTT and Tris-HCl 8.0/MgCl2. 20 μl of the mix (for 4 
reactions) were then mixed with 6 μl of either 500 mM NaCl/20 mM TrisTRI-HCl 8/20% 
glycerol or proteins MOV10, HsSUV3 or ScPRP2 suspended in this buffer. The mixes 
were incubated in ice for 5 min. Thereafter 4x 6 μl from each condition were mixed 
with 1 μl 20 mM Tris-HCl 8/20 mM NaCl or increasing concentrations of recombinant 
L1-ORF1p in this buffer (prepared as set of dilutions) to final L1-ORF1p in 10μl: 0, 5, 
10, 20 nM. The mixes were incubated for 5 min in ice. Thereafter 2.5 μl of TUT4/cold 
trap DNA were added and reactions immediately placed at 37 °C in 30 sec intervals. 
Reactions were incubated for 18 min keeping the time intervals and then rapidly 
stopped by addition of 100μl TNES (Tris-HCl 8/NaCl/EDTA/SDS) supplemented with 
20 ng/μl proteinase K (USB). RNA was purified by 2 rounds of 
phenol/chloroform/isoamyl alcohol 25:24:1 extraction, precipitated with ethanol (after 
addition of 1.5 μl GlycoBlue precipitant to each sample) and resolved in a 9.6% 
denaturing PAGE with single nucleotide resolution, scanned and quantified using 
MultiGauge software. 
 
With 5’ FAM-labelled RNA, L1-ORF1p and TUT7 
FAM-labelled 44-mer RNA (RNA44, 50 nM, Future Synthesis) was combined with 
0.5 mM UTP in 0.5x NEB2 buffer (home-made, 1x: 10 mM Tris-HCl pH 8, 50 mM 
NaCl, 10 mM MgCl2, 1 mM DTT). Recombinant L1-ORF1p (or respective buffer) was 
added to the indicated concentration (0-150 nM) and samples were incubated 5 min 
at RT. Purified TUT7 WT was then added to 0.5 nM and the samples were incubated 
at 37 °C for 10 min. The reactions were stopped by the addition of proteinase K (USB) 
in 100 μl TNES (50 mM Tris-HCl pH 8, 100 mM NaCl, 10 mM EDTA, 1% SDS) and 
purified as described in “RNA isolation”. Finally, the RNA was dissolved in 4 μl 
standard formamide loading dye, loaded onto an 8% denaturing PAGE gel (20 x 20 x 
0.04 cm; 28 lanes) and separated for 70 min at 700 V. The gel was immediately 
scanned using a FLA-9000 apparatus (GE Healthcare). 
 
In vitro RNase I footprinting assay 
Production of 32P-labelled RNA 
DNA templates for in vitro RNA transcription were produced by PCR using the 99 
PUR RPS EGFP plasmid as a template and forward and reverse primers 
(T7_L13UTRef gtgagagatgtaatacgactcactataggGGAACTCCATATATGGGCTAT- the 
T7 promoter is underlined and preceded by several stabilizing nucleotides; and 
L13UTRrv, TAGGGTACATGTGCACATTGC). The purified DNA was used for two in 
vitro run-off transcription reactions, “cold” and “hot”, using home-made T7 RNA 
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polymerase to generate 79 nt RNAs. Random 32P labelling was accomplished using 
0.5 mM rATP/rCTP/rGTP and 0.1 mM UTP supplemented with 0.1 μM 32P UTP that 
resulted in labelling of ~1 of 50 transcripts. “Cold” and “hot” RNAs were separated 
from the template and shorter products by 6% denaturing PAGE. The relevant bands 
were excised (after exposure to a film and its development in AFGA Curix CP-1000 
device or by illumination with UV of the gel placed on TLC with a fluorescent indicator) 
and the nucleic acids were eluted overnight in REB (0.3 M sodium acetate pH 5.2, 
3 mM EDTA, 1:17 vol/vol of a 25:24:1 phenol/chloroform/isoamyl mixture) followed by 
ethanol precipitation. 
 
Footprinting 
RNase I RNA footprinting was performed as described in Razew et al., 2018 with 
modifications. Cold and hot L1-3´UTR RNA (125 nM; final concentration in 10 μl was 
50 nM or ~400 cps per sample) were combined in 0.5x NEB2 buffer (home-made, 1x: 
10 mM Tris-HCl pH 8, 50 mM NaCl, 10 mM MgCl2, 1 mM DTT) with 2.5 mM ATP (1 
mM final concentration in 10 μl) on ice. Recombinant MOV10 or respective buffer 
was then added where indicated to 22 nM (15 nM final concentration in 10 μl) and 
samples were moved to RT before recombinant ORF1 was added to a final 
concentration of 0, 20, or 100 nM in 10 μl. After 2 min, “cold trap DNA” (100 nM final 
concentration in 10 μl) and the 26A13G primer was added to all samples to bind 
ORF1 released from the RNA by MOV10 and to prevent rebinding to the RNA, 
followed by the addition of 1 μl Ambion RNase I (100 U; Thermo Fisher Scientific). 
The RNA was degraded with RNase I for 25 min at 25 °C and the reaction was 
stopped with 10 μl proteinase K (200 ng; USB) in TNES (50 mM Tris-HCl pH 8, 
100 mM NaCl, 10 mM EDTA, 1% SDS) and purified as described in “RNA isolation”. 
Glycoblue (2 μl) was added to the reaction mixture to obtain an aqueous phase. 
Sodium acetate (50 mM, pH 5.2) was then added and the mixture was precipitated 
for 2 h at -20 °C. The RNA was centrifuged, dissolved in 4 μl formamide loading dye 
and separated on an 8% PAGE gel (30 x 20 x 0.04 cm) at 1250 V for 2 h at RT. The 
gel was exposed to a phosphorimager screen (Fuji) and scanned using a Fuji 
PhosphorImager (FLA7000). 
 
Immunofluorescence 
Preparation of cells 
To visualize EGFP-tagged proteins, parental HEK 293 FLP-In T-Rex cells were 
seeded in 6-well plates at 0.3x106 cells per well and transfected on the following day 
with 2 μg pZW plasmid encoding the indicated N-terminal EGFP-tagged protein using 
7 μl Lipofectamine 2000 (ThermoFisher Scientific) in 300 μl OPTI-MEM (Gibco). Cell 
lines stably expressing the indicated proteins were also used and treated as 
described below. 
For co-localization studies of L-1ORF1p-FLAG and endogenous TUT7 and MOV10, 
HEK 293 FLP-In T-Rex cells were transfected as above but instead using 0.75 μg 
pZW-L1RP-O1F plasmid and 5 μl Lipofectamine 2000. 
Next day cells were trypsinized and 1/5 of the cells was reseeded onto polylysine-
coated glass slides in new 6-well plate wells or ~33x103 cells were seeded in a single 
well of a 8-well Nunc Lab Tek II Chamber slides (for in vivo microscopy) in medium 
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supplemented with 100 ng/ml tetracycline. Cells were analyzed 24-48h after seeding 
either as live cells or after fixation and staining. 
 
Cell fixation and protein staining 
To examine immunofluorescence of fixed cells, the medium was removed from the 
chamber and the cells were gently washed twice with PBS at 37 °C. The cellular 
contents were fixed by overlaying 3.7% formaldehyde (from 37% aqueous solution) 
and 5% sucrose in PBS at RT for 15 min, after which the cells were washed with RT 
PBS three times. The cells were then permeabilized with 0.2% Igepal CA-630 (NP40) 
with 10% FBS in PBS for 15 min at RT. The permeabilized cells were washed once 
with RT PBS and incubated in 10% FBS in PBS for 15 min at RT. After removing the 
solution, primary antibodies (see Key Resources table) were added at 1:50 (FLAG, 
TUT4, TUT7) to 1:200 (MOV10) dilutions. Monoclonal mouse anti-FLAG M2 
antibodies (Sigma) yielded reproducible L1-ORF1p-FLAG staining. Monoclonal rabbit 
anti-FLAG antibody F2555 (Sigma) performed well after delivery and when stored at 
4 °C, but showed no binding after freezing and thawing. The cells were incubated 
with the antibodies for 1 h at RT, washed three times with PBS and secondary 
Alexa488/555/647-coupled antibodies (depending on the staining) in 10% FBS in 
PBS were overlaid at 1:800 and incubated for 1 h at RT. The antibodies were then 
removed and the cells were overlaid with 1:10,000 Hoechst in PBS for 10 min at RT 
to stain DNA. The cells were washed three times with PBS and the slides were 
mounted using ProLong Gold Antifade (Thermo Fisher Scientific) and left in the dark 
at RT to dry overnight. 
 
Microscopic analysis 
Imaging was performed using a FluoView1000 Olympus confocal system with a 
PLANAPO 60x/1.40 oil immersion lens. Live cell imaging was performed at 37 °C in a 
humidified 5% CO2 incubator. Cross-talk was tested and eliminated using bandpass 
filters. 
 
Quantification of co-localization cytoplasmic foci 
The foci were identified by the presence of enriched MOV10 staining. Enrichment of 
plasmid-encoded TUT4 and TUT7 was assessed by merging images (confocal 
microscopy channels) in a single frame and visual inspection. 
 
Quantification and Statistical Analysis 
Quantification of LC-MS/MS data 
Raw data files were used to calculate semi-quantitative measures of protein 
abundances in the samples using MaxQuant software version 1.3.0.5 (Cox and Mann, 
2008) and default settings including DSP-acetamide modification and setting 
multiplicity to 1. Database used for uniprot_human protein sequence database as of 
Feb. 2013.  
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Estimation of L1-ORF1p and ORF2p translation 
Analysis of L1-ORF1p and L1-ORF2p translation was performed using Attune NxT 
software and reported in terms of EGFP and mCherry intensities. Laser intensities 
accommodated the entire fluorescence range without saturation. Singlet cells were 
analyzed based on initial FSC-A/SSC-A gating (gate 1) and subsequent FSC-H/FSC-
A gating (gate 2 used for further analysis). Gates for EGFP+ and mCherry+ cells 
were then set according to control cells that were not fluorescent. Less than 0.02% of 
cells among the control cell population were allowed within the EGFP+ or mCherry+ 
gates. 
 
Data and Software Availability 
All mRNA expression data that support the findings of this study have been 
deposited at GEO under accession numbers (GSE105264). 
The primary data and output of the RACE-seq pipeline can be retrieved from 
http://adz.ibb.waw.pl/warkocki-et-al-2018 
The scripts used in the analysis of the RACE-seq output can be found at 
https://github.com/smaegol/LINE_1_RACE_seq_analysis 
Other data used to generate figures including uncropped blots and Prism files can be 
found at http://dx.doi.org/10.17632/zkb2nr99rw.1 
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Supplementary Table Legends 
 
Table S1 List of oligonucleotides used in 3’ RACE-seq, Related to Figure 2 
 
List of DNA oligonucleotides (adapter, primers and spike-ins) used in preparation of 3’ 
RACE-seq libraries. Given are names of the oligonucleotides, their sequences and 
what they were used for. 
 
Table S2 3’ RACE-seq data, Related to Figure 2 
 
3’ RACE-seq analysis of the 3’ ends of endogenous and reporter L1 and control 
mRNAs. Following data are provided: (i) internal reference number; (ii) experimental 
condition where: “proteinnameKD” denotes knock down of the protein; “protein name” 
denotes overexpression; “NT” denotes no transfection; (iii) number of the biological 
replicate; (iv) cell line; (v) name of the primer used in 3’ RACE-seq amplification; (vi) 
analyzed mRNA species; (vii) localization where: “total” denotes whole cell; “CYTO” 
denotes cytoplasmic fraction after cell fractionation; “NUC” denotes” nuclear fraction 
after cell fractionation; (viii) identifier of the sequencing run; (ix) status of uridylation 
where: “FALSE” denotes non-uridylated mRNAs and “TRUE” denotes uridylated 
mRNAs; (x) number of sequenced and analyzed reads, (xi) mean number of As in A-
tails (nucleotides); (xii) mean number of As in AU-tails (nucleotides); (xiii) mean 
number of Us in AU-tails (nucleotides); (xiv) mean number of Us in U-tails 
(nucleotides). 
 
Table S3 Mass spectrometry of a single co-IP with L1-ORF1p-FLAG from a HEK293 
FLP-In T-Rex stable cell line, Related to Figure 4 
 
Analysis of the mass spectrometry results of the L1-ORF1p-FLAG co-IP and its 
relevant control performed using MaxQuant software. Only proteins specifically 
enriched in the L1-ORF1p-FLAG co-IP and not identified in the control co-IP are 
included. 
 
Table S4 Differential expression analysis of L1s in overexpression conditions, 
Related to Figure 4 
 
Analysis of the expression of L1s in cells overexpressing TUT4, TUT7 or MOV10. 
Sequencing reads were mapped against the human genome (ver. hg38) using STAR 
and counted using TEtranscripts for repetitive elements quantification. Differential 
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expression analysis was done using DESeq2. Table shows Log2 Fold Change and 
adjusted p values (padj) of each of LINE class included in the analysis for each 
condition tested (in relation to control samples), calculated by DEseq2. 
 
Table S5 Differential expression analysis of L1s in depletion conditions, Related to 
Figure 4  
Analysis of the L1s expression in cells depleted of TUTases and MOV10. 
Sequencing reads were mapped against human genome (ver. hg38) using STAR 
and counted using TEtranscripts for repetitive elements quantification. Differential 
expression analysis was done using DESeq2. Table shows Log2 Fold Change and 
adjusted p values (padj) of each of LINE class included in the analysis for each 
condition tested (in relation to control samples), calculated by DEseq2. 
 
Table S6 Mass spectrometry of EGFP-TUT4, EGFP-TUT7 and control co-IPs, 
Related to Figure 5 
 
Analysis of the mass spectrometry results of EGFP-TUT4 and EGFP-TUT7 co-IPs 
(with in vivo DSP protein-protein cross-linking and without any crosslinking) and their 
relevant controls performed using MaxQuant software. In aggregate, following 
number of co-IPs for the indicated proteins were analyzed: 6 for EGFP control with 
DSP crosslinking, 6 for EGFP-TUT4 with DSP cross-linking, 7 for EGFP-TUT7 with 
DSP cross-linking, 6 for control EGFP/HEK293 FLP-IN T-Rex, 7 for EGFP-TUT4, 3 
for EGFP-TUT7. Color-coded columns show: (i) normalized mean intensities divided 
by the detected protein molecular mass, (ii) specificities (i.e., quotient of normalized 
mean intensities divided by the proteins’ molecular mass in test and control co-IPs). 
Further, columns show how many times a protein was detected in the indicated sets 
of co-IPs. The remaining columns are parameters returned by the MaxQuant 
software as described in its on-line manual and Cox and Mann, 2008. The header of 
each column is presented in the following manner X Y_(Z)_S_(W)_L where X 
specifies the MaxQuant parameter, and Y_(Z)_S_(W)_L specify the co-IP conditions 
in the following order: Y – protein, Z – “DSP” indicates DSP cross-linking, not 
indicated if not applicable, S – NaCl concentration in mM, W – “RN” indicates 
inclusion of RNase A in the co-IP, not indicated if not applicable, L – the biological 
replicate within a series. 
 
Table S7 Mass spectrometry of EGFP-MOV10 and control co-IPs, Related to Figure 
5 
 
Analysis of the mass spectrometry results of EGFP-MOV10 co-IPs (with in vivo DSP 
protein-protein cross-linking and without any crosslinking) and their relevant controls 
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performed using MaxQuant software. In aggregate, following number of co-IPs for the 
indicated proteins were analyzed: 5 for EGFP control with DSP crosslinking, 7 for 
EGFP-MOV10 with DSP cross-linking. Color-coded columns show: (i) normalized 
mean intensities divided by the detected protein molecular mass, (ii) specificities (i.e., 
quotient of normalized mean intensities divided by the detected protein molecular 
mass in test and control co-IPs). Further, columns show how many times a protein 
was detected in the indicated sets of co-IPs. The remaining columns are parameters 
returned by the MaxQuant software as described in its on-line manual and Cox and 
Mann, 2008. The header of each column is presented in the following manner X 
Y_(Z)_S_(W)_L where X specifies the MaxQuant parameter, and Y_(Z)_L the co-IP 
conditions in the following order: Y – protein, Z – “DSP” indicates DSP cross-linking, 
not indicated if not applicable, L – the biological replicate within a series. All co-IPs 
were done with addition of RNase A, followed by washing with buffer containing 
500 mM NaCl. 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit polyclonal anti-ZCCHC11 (TUT4) Proteintech 18980-1-AP 
Rabbit polyclonal anti-ZCCHC6 (TUT7) Sigma HPA020620 
Rabbit polyclonal anti-MOV10 Abcam Ab80613 
Mouse monoclonal anti-hDCP1A Santa Cruz 
Biotechnology 
sc100706 
Mouse monoclonal anti-FLAG Sigma-Aldrich F1804 
Rabbit monoclonal anti-FLAG Sigma-Aldrich F2555 
Rabbit polyclonal anti-GAPDH Novus Biologicals NB300-327 
Mouse monoclonal anti--tubulin Sigma-Aldrich T6557 
Rabbit monoclonal anti-Histone H4 Merck Cat. #05-858 
Mouse monoclonal anti-MBP NEB E8032S 
Rabbit polyclonal anti-PABP Abcam Ab21060 
Chemicals, Peptides, and Recombinant Proteins 
Phusion HF polymerase Thermo Fisher 
Scientific 
F530L 
TRI Reagent Sigma-Aldrich T9424 
Lipofectamine 2000 Thermo Fisher 
Scientific 
11668019 
Lipofectamine RNAiMAX Thermo Fisher 
Scientific 
13778150 
CNBr-activated SepFast MAG 4HF beads BioToolomics 310202 
Anti-FLAG M2 affinity gel Sigma-Aldrich A2220 
Dynabeads Protein-G coupled Thermo Fisher 
Scientific 
10004D 
GFP-Trap Chromotek gtma100 
Amylose resin NEB E8021L 
Agencourt AMPure XP magnetic beads Beckman Coulter A63880 
TURBO DNase Ambion AM2239 
T4 RNA ligase 2, truncated NEB M0242L 
SuperScript III Reverse Transcriptase Invitrogen 18080-085 
Key Resource Table
Viscolase A&A 
Biotechnology 
1010-100 
PerfectHyb Plus hybridization buffer Sigma H7033 
Critical Commercial Assays 
Ribo-Zero Gold rRNA-removal kit H/R/M Illumina RZG1224 
KAPA Stranded RNA-seq Library Preparation 
Kit for Illumina platforms 
KAPA Biosystems KR0934 
Platinum SYBR Green qPCR SuperMix-UDG Thermo Fisher 
Scientific 
11733046 
Clean-up RNA Concentrator Kit A&A 
Biotechnology 
039-100C 
TaqMan™ Fast Advanced Master Mix Thermo Fisher 
Scientific 
4444556  
TaqMan™ Gene Expression Assay (GAPDH, 
VIC dye) 
Thermo Fisher 
Scientific 
4448490 
TaqMan™ primers and probe with FAM dye 
(TAQMAN_EGFPI_2_PROBE) 
Thermo Fisher 
Scientific 
4331348  
Actinomycin D Roth 8969.1 
Deposited Data 
RNA-seq data GEO 
(GSE105264) 
This paper 
3’ RACE-seq data http://adz.ibb.waw.
pl/warkocki-et-al-
2018 
This paper 
The scripts used to analyse the RACE-seq 
data 
https://github.com/
smaegol/LINE_1_
RACE_seq_analys
is 
This paper 
Data used for Figure production http://dx.doi.org/10
.17632/zkb2nr99r
w.1 
This paper 
Experimental Models: Cell Lines 
HEK293 FLP-In T-Rex EGFP-TUT4 This paper  
HEK293 FLP-In T-Rex EGFP-TUT7 This paper  
HEK293 FLP-In T-Rex EGFP-MOV10 This paper  
HEK293 FLP-In T-Rex parental Invitrogen R78007 
HEK 293T 
Invitrogen  
Human foreskin fibroblasts (HFFs). Jose L. Garcia-
Perez Lab; cells 
originally 
purchased from 
ATCC. 
 
Human embryonic carcinoma PA-1 Jose L. Garcia-
Perez Lab; cells 
originally 
purchased from 
ATCC. 
 
Human embryonic stem cells H9 Jose L. Garcia-
Perez Lab; cells 
originally 
purchased from 
Wicell 
 
Neuron progenitor cells (NPCs differentiated 
from H9-hESCs) 
Jose L. Garcia-
Perez; We 
differentiated 
hESCs to NPCs 
using a previously 
validated protocol 
(Macia et al., 
2017) 
 
FreeStyle 293-F cells Invitrogen R79007 
Experimental Models: Organisms/Strains 
C57BL/6 mice This paper  
Oligonucleotides 
RA3_15N (3' adapter) 
/5rApp/CTGACNNNNNNNNNNNNNNNTGGA
ATTCTCGGGTGCCAAGG/3ddC/ 
Integrated DNA 
Technologies 
(IDT); this paper 
 
Spike-in_0 (without poly(A); fixed index = 19) 
AATGATACGGCGACCACCGAGATCTACAC
GTTCAGAGTTCTACAGTCCGACGATCNNN
NNNNNNNNNNNNNNNNNNNNCTGACGAG
CTACTGTTGGAATTCTCGGGTGCCAAGGA
ACTCCAGTCACGTGAAAATCTCGTATGCCG
TCTTCTGCTTG 
IDT; this paper  
Spike-in_8 (fixed index = 20) 
AATGATACGGCGACCACCGAGATCTACAC
GTTCAGAGTTCTACAGTCCGACGATCNNN
NNNNNNNNNNNBAAAAAAAACTGACGAG
CTACTGTTGGAATTCTCGGGTGCCAAGGA
ACTCCAGTCACGTGGCCATCTCGTATGCC
GTCTTCTGCTTG 
IDT; this paper  
Spike-in_16 (fixed index = 21) 
AATGATACGGCGACCACCGAGATCTACAC
GTTCAGAGTTCTACAGTCCGACGATCNNN
NNNNNNNNNNNBAAAAAAAAAAAAAAAA
CTGACGAGCTACTGTTGGAATTCTCGGGT
GCCAAGGAACTCCAGTCACGTTTCGATCTC
GTATGCCGTCTTCTGCTTG 
IDT; this paper  
Spike-in_32 (fixed index = 22) 
AATGATACGGCGACCACCGAGATCTACAC
GTTCAGAGTTCTACAGTCCGACGATCNNN
NNNNNNNNNNNBAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAACTGACGAGCTACT
GTTGGAATTCTCGGGTGCCAAGGAACTCC
AGTCACCGTACGATCTCGTATGCCGTCTTC
TGCTTG 
IDT; this paper  
Spike-in_64-5 (for splint ligation with the 3’ 
part) 
AATGATACGGCGACCACCGAGATCTACAC
GTTCAGAGTTCTACAGTCCGACGATCNNN
NNNNNNNNNNNBAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAC 
IDT; this paper  
Spike-in_64-3-P (for splint ligation with the 5’ 
part; fixed index = 23) 
/5Phos/TGACGAGCTACTGTTGGAATTCTC
GGGTGCCAAGGAACTCCAGTCACGAGTGG
ATCTCGTATGCCGTCTTCTGCTTG 
IDT; this paper  
Spike-in splint (for splint ligation) 
TCCAACAGTAGCTCGTCAGTTTTTTTTTTTT
TTTTT 
IDT; this paper  
RNA44 
(CGACUGGAGCACGAGGACACUGACAUGG
ACUGAAGGAGUAGAAA) 
Future Synthesis; 
this paper 
 
Other 
Stealth RNAi siRNA Negative Control Hi GC Invitrogen 12935400 
Stealth RNAi siRNA targeting ZCCHC11 
(TUT4) #1 (HSS146317), #2 (HSS146319), 
#3 (HSS177328) 
Invitrogen 10620318/ 
10620319 
Stealth RNAi siRNA targeting ZCCHC6 (TUT7) 
#1 (HSS149223) – not functional, 
#2 (HSS149224), #3 (HSS149225) 
Invitrogen 10620318/ 
10620319 
Stealth RNAi siRNA targeting MOV10 
#A (HSS106675), #C (HSS106677) 
Invitrogen 10620318/ 
10620319 
Stealth RNAi siRNA targeting TUT1 
(HSS127841) 
Invitrogen Mroczek et al., 
2013 
Recombinant DNA 
99 PUR RPS EGFP John Goodier; 
Goodier et al., 
2012 
 
99 PUR JM111 EGFP John Goodier; 
Goodier et al., 
2012 
 
JM101/L1.3 nomarker Jose L. Garcia 
Perez Lab. 
 
JM101/L1.3-O1EGFP-O2cherry (EGFP-tagged 
L1-ORF1p, mCherry-tagged L1-ORF2p, on a 
full-length L1.3 element containing the mneoI 
retrotransposition indicator cassette) 
Jose L. Garcia 
Perez Lab. 
 
pZW-L1RP-O1F (FLAG-tagged L1-ORF1p on 
a full-length L1RP element) 
This paper  
pZW-L1RP-O1F-megfpI (FLAG-tagged 
L1-ORF1p on a full-length L1RP element 
tagged with the megfpI retrotransposition 
indicator cassette) 
This paper  
pZW-L1RP-O1mCh (mCherry-tagged 
L1-ORF1p on a full-length L1RP element) 
This paper  
pZW-L1RP-O1mCh-megfpI (mCherry-tagged 
L1-ORF1p on a full-length L1RP element 
tagged with the megfpI retrotransposition 
indicator cassette) 
This paper  
pZW-L1RP-O2G (EGFP-tagged L1-ORF2p on 
a full-length L1RP element) 
This paper  
pZW-L1RP-megfpI (Active full-length L1RP 
element tagged with the megfpI, containing a 
CMV promoter upstream of L1RP, giving high 
retrotransposition rates without a need for 
antibiotic selection)  
This paper  
pZW-L1RP-megfpI-TRL (“blunt ended” L1RP 
megfpI reporter due to excision of the tRNA-
like element, see below for details) 
This paper  
pZW-L1RP-megfpI-xyz-TRL (megfpI tagged 
L1RP where xyz specifies the 3’ tail, for 
example 26A or 19A3U see methods for 
details) 
This paper  
pZW plasmids for generation of stable cell 
lines and transient overexpression of TUT4, 
TUT7, MOV10, TENT4B, TENT2 proteins with 
N-terminal EGFP, mCherry, MBP or FLAG 
tags 
This paper  
Plasmid for overexpression of TUT1-FLAG Mroczek et al., 
2013 
 
Plasmid for overexpression of TENT5C-FLAG Mroczek et al., 
2017 
 
Software and Algorithms 
Prism 5 for Windows https://www.graph
pad.com/scientific-
software/prism/ 
 
Attune NxT flow cytometry software provided 
with the Attune NxT instrument 
Thermo Fisher 
Scientific 
 
MultiGauge 5.1 Fuji Film 
(discontinued) 
 
ImageJ https://imagej.nih.g
ov/ij/ 
 
SnapGene 3.3.4 www.snapgene.co
m/ 
 
MaxQuant 1.3.0.5. http://www.coxdoc
s.org/doku.php?id
=maxquant:comm
on:download_and_
installation#downlo
ad_and_installatio
n_guide 
 
Flowing Software by Perttu Terho http://flowingsoftw
are.btk.fi/ 
 
Tailseeker3 https://github.com/
hyeshik/tailseeker 
Chang et al., 
2014 
TEToolkit https://github.com/
mhammell-
laboratory/tetoolkit 
Jin et al., 2015 
STAR https://github.com/
alexdobin/STAR 
Dobin et al., 
2013 
Bowtie2  http://bowtie-
bio.sourceforge.ne
t/bowtie2/index.sht
ml 
Langmead and 
Salzberg, 2012 
Repeatmasker  http://www.repeat
masker.org/ 
Smit et al., 2013 
Sabre https://github.com/
najoshi/sabre 
 
RACE-seq analysis scripts https://github.com/
smaegol/LINE_1_
RACE_seq_analys
is 
This paper 
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Clone 1 TACTATTAGCCCGGGCTTTTTTTTTTT---------------CCTATAGTGAGTCGTATTAATTCTGTGCTCGC 11
Clone 2 heterogenous
Clone 3 TACTATTAGCCCGGGCTTTTTTTTTTTT--------------CCTATAGTGAGTCGTATTAATTCTGTGCTCGC 12
Clone 4 TACTATTAGCCCGGGCTTTTTTTTTTTTTTTTTTTTTTTTTTTTCCTATAGTGAGTCGTATTAATTCTGTGCTCGC 28
Clone 5 TACTATTAGCCCGGGCTTTTTTTTTTTTTTTTTTTTTTTTTTTCCTATAGTGAGTCGTATTAATTCTGTGCTCGC 27
Clone 6 TACTATTA followed by an unknown sequence
Clone 7 TACTATTAGCCCGGGCTTTTTTTTTTTTTTTTTTTTTTT---CCTATAGTGAGTCGTATTAATTCTGTGCTCGC 23
Clone 8 TACTATTAGCCCGGGCTTTTTTTTTTTTTTTTTTT-------CCTATAGTGAGTCGTATTAATTCTGTGCTCGC 19
Clone 9 TACTATTAGCCCGGGCTTTTTTTTTTTTTTTTTTTTTT----CCTATAGTGAGTCGTATTAATTCTGTGCTCGC 22
Clone 10 TACTATTAGCCCGGGCTTTTTTTTTTTTTTTTTTTTTT----GACGCTGGTGAGTCGTATTAATTCTGTGCTCGC 22
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